前往化源商城

4452-06-6 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SERCaMPGLuc-p1-antagonist
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 5 uL; 1000 SH-SY5Y cells per wells
2; Time; 5 hour; 37C, 5% CO2
3; Compound; 23 nL; Control inhibitor / compound library
4; Time; 16 hour; 37C, 5% CO2
5; Reagent; 100 nM; Thapsigargin
6; Time; 4 hour; 37C, 5% CO2
7; Reagent; 1 uL; 0.5x coelenterazine
8; Detection; Luminescence; ViewLux imaging system

NOTES (numbers refer to sequence above)
1; SH-SY5Y human neuroblastoma cells stably expressing GLuc-SERCaMP (SH-SY5Y-GLuc-ASARTDL) cells were seeded in 1,536 well white tissue culture treated plates (Corning, Cat# 7464) in DMEM-high glucose-sodium pyruvate (ThermoFisher Scientific, Cat #10569) supplemented with 10% bovine growth serum (Hyclone), 10 U/ml penicillin (Gibco), 10 ug/ml streptomycin (Gibco), and 20 mM HEPES.
2; Assay plates were incubated for 5 hour at 37C in a humidified incubator containing 5% CO2.
3; qHTS libraries (23 nl, final concentrations of 1.53 uM, 7.67 uM, 38.3 uM) or controls (neutral control: DMSO, positive control: dantrolene) were added using a Kalypsis pin-tool Robotic System equipped with 1536 pinheads.
4; Cells were then incubated for 16 hours at 37C, 5% CO2.
5; Thapsigargin was added at 100 nM to deplete ER calcium stores.
6; Cells were incubated for 4 hour (37oC, 5% CO2)
7; Gaussia luciferase in the medium was measured by adding 1 ul of 0.5x coelenterazine (final concentration 0.07x) prepared in Gaussia Luciferase Glow Assay Buffer (Pierce), without addition of the Cell Lysis Buffer Reagent.
8; Luminescence was measured using a ViewLux high-432 throughput CCD imaging system (Perkin Elmer) equipped with clear filters. Compounds exhibiting inhibitory activity (defined as curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4, -3) were identified by normalizing plate-wise to corresponding intra-plate controls (neutral control = Tg only; positive control (100% inhibition) = DMSO vehicle) with percent activity derived using in-house software (https://tripod.nih.gov/curvefit). The same controls were also used for the calculation of the Z' factor, a measure of assay quality control, as previously described (Zhang et al., 1999). For the initial validation of activity in the SERCaMP assays, hits from the primary screen were assayed again at 11-concentrations (1.3 nM - 76.6 uM). SH-SY5Y-GLuc-SERCaMP cells were assayed for ER Ca2+ depletion as outlined above.

Reference:
1. Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000259387 uMActivity at 0.0000710850 uMActivity at 0.0001271514 uMActivity at 0.0003024044 uMActivity at 0.0005030064 uMActivity at 0.0006524306 uMActivity at 0.00193 uMActivity at 0.00341 uMActivity at 0.00584 uMActivity at 0.010 uMActivity at 0.018 uMActivity at 0.052 uMActivity at 0.078 uMActivity at 0.156 uMActivity at 0.276 uMActivity at 0.478 uMActivity at 0.883 uMActivity at 1.507 uMActivity at 3.884 uMActivity at 7.354 uMActivity at 12.96 uMActivity at 21.63 uMActivity at 38.41 uMActivity at 76.33 uMActivity at 137.0 uMActivity at 204.0 uMCompound QC
Inhibitor1104.966488Complete curve; high efficacy-63.51170.6658-104.96640-1.10 0 0-97.13-85.6484-112.8671-97.13QC'd by Tocris
Inhibitor0.316259.327888Complete curve; high efficacy-6.50.81-84.7193-25.3915-1.10 0 0-83.9327-75.7429-81.922-83.9327QC'd by BIOMOL
Inhibitor3.162320.498785Complete curve; high efficacy-5.54.95490.4756-107.8212-87.3224-1.10 0 0-101.1849-96.9354-114.4343-101.1849QC'd by SIGMA
Inhibitor0.749266.151166Complete curve; partial efficacy-6.125410.8229-74.6135-8.4624-1.20 0 0 0 0 0 0 0 0 0 0-67.099-7.8787-22.7216-1.4525-29.6562-23.5194-8.332-25.0891-62.4832-68.6466-63.9027-67.099QC'd by Microsource
Inhibitor121.684566Complete curve; partial efficacy-64.95490.9699-77.7873-56.1028-1.20 0 0-76.43-65.0857-78.9894-76.43QC'd by BIOMOL
Inhibitor1.12259.675865Complete curve; partial efficacy-5.951.210.9999-66.8495-7.1736-1.20 0 0-66.096-42.6313-61.4055-66.096QC'd by Vitas
Inhibitor1.995334.026364Complete curve; partial efficacy-5.74.95490.9891-73.9118-39.8855-1.20 0 0-72.1972-47.1162-75.3813-72.1972QC'd by SigmaAldrich
Inhibitor12.589337.266562Complete curve; partial efficacy-4.911-78.1117-40.8452-1.20 0 0-68.8431-44.9463-54.9089-68.8431QC'd by Tocris
Inhibitor14.125432.429762Complete curve; partial efficacy-4.851.22160.9999-88.7022-56.2725-1.20 0 0-81.3177-58.1227-66.7029-81.3177QC'd by Enzo
Inhibitor1029.898362Complete curve; partial efficacy-53.29750.9999-76.1051-46.2067-1.20 0 0-75.9694-46.234-54.866-75.9694QC'd by Microsource
Inhibitor11.220226.849761Complete curve; partial efficacy-4.954.0950.9996-65.1082-38.2585-1.20 0 0-65.0072-38.2023-43.2866-65.0072QC'd by SigmaAldrich
Inhibitor25.118945.784461Complete curve; partial efficacy-4.61.53861-101.459-55.6745-1.20 0 0-85.8367-56.2934-62.0903-85.8367QC'd by SigmaAldrich
Inhibitor31.622832.29860Complete curve; partial efficacy-4.52.18760.9999-141.8428-109.5448-1.20 0 0-129.0357-109.6207-111.066-129.0357QC'd by Microsource
Inhibitor31.622835.977260Complete curve; partial efficacy-4.51.10.9999-99.0432-63.0659-1.20 0 0-82.9526-64.2216-69.1965-82.9526QC'd by Microsource
Inhibitor35.481337.624260Complete curve; partial efficacy-4.454.95490.9762-81.2779-43.6537-1.20 0 0-66.0936-45.7944-41.8015-66.0936QC'd by Tocris
Inhibitor35.481350.188560Complete curve; partial efficacy-4.454.44950.9982-87.6877-37.4992-1.20 0 0-66.8089-38.2236-36.8414-66.8089QC'd by Pharmacopeia
Inhibitor35.481347.340560Complete curve; partial efficacy-4.454.95490.9906-107.1544-59.8139-1.20 0 0-87.9757-61.3159-58.1701-87.9757QC'd by Prestwick Chemical; Inc.
Inhibitor5.9508124.625145Partial curve; high efficacy-5.22542.72020.864-126.7319-2.1068-2.10 0 0 0 0 0 0 0 0 0 1000-13.748-1.3723-25.9483-11.282526.65188.4521-36.83-113.80310QC'd by ChemAxon
Inhibitor11.873489.544142Partial curve; partial efficacy-4.92541.24750.9863-91.1278-1.5837-2.20 0 0 0 0 1 0 0 0 0 0-74.7046000-4.6868-8.0974-38.15161.1319-8.2196-21.8072-47.3218-74.7046QC'd by Cayman
Inhibitor25.1189267.383841Partial curve; partial efficacy-4.64.95490.8835-100.7065166.6773-2.20 0 0-71.9482116.4983215.4265-71.9482QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1218362
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1218361
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1218360
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1315
Protocol: Cybrid cells were washed with PBS, trypsinized, spun down at 300g for 5 minutes, and resuspended in 10 mLs of PBS. Cells were counted, and the appropriate amount of cells were added to a vial containing DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose, DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 0.3% DMSO, DMEM No Glucose + 2% FBS + 1% P/S + 10mM Galactose + 1uM I-BET GSK 525762A, or DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 1.25mM Glucose. Cells were then seeded in a Corning 3570 384-well plate (40 ul/well,1500 cells/well). Two replicates were prepared as described at the same time per library plate.

100 nl of compound was added to each well via pin transfer immediately after seeding. After the addition of compound, cells were incubated for 72 hours at 37 degrees C with 5% CO2.

Following the 72 hour incubation period, the 384 well plates were centrifuged for 1 minute at 1000 rpm. The media was aspirated using an aspiration wand and fresh media DMEM only, was added to the cells (40uL/ well) using a well-mate. Fifteen-microliters of Cell Titer Glow substrate was then added to each well using the well-mate. The plates were gently vortexed for 10 seconds and then centrifuged for 1 minute at 1000 rpm. The plates were then immediately read on the Envision instrument and the luminescence was detected for each individual well.

Positive control (strong): Cells seeded in DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 1.25mM Glucose
Positive control (weak): Cells seeded in DMEM No Glucose + 2% FBS + 1% P/S + 10mM Galactose + 1uM I-BET GSK 525762A
Negative control: Cells seeded in DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 0.3% DMSO
Comment: Data analysis method and criteria for scoring active compounds:

Z-scores were calculated for both replicates separately using the plate average and standard deviation of experimental well luminescence (Z = (x - mu)/sigma). Compounds were considered active if both replicate Z-scores >= 1.8. Activity scores were determined by scaling replicate average Z-scores from 0 (activity score = 0) to 4 (activity score = 100), with activity score > 45 being considered active. Z-scores < 0 were set to activity score = 0; Z-scores > 4 were set to activity score = 100 (100% activity).
Luminescence_ALuminescence_BZ-score Rep AZ-score Rep B
15087591941614-0.29-0.43
17411761927012-0.01-0.44
197614624877510.290.11
347045740451192.151.64
244929828664190.880.48
15633732388055-0.230.01
182721124299270.10.05
235000430356-1.88-1.91
15443152345114-0.25-0.03
182392827546700.10.37
10776522101177-0.83-0.27
190465327072880.20.33
327799138504031.911.45
16951292723755-0.060.34
401368547421142.822.33
245078133481490.880.96
253134330714220.980.69
229493728987220.680.52
16507292422255-0.120.05
12125591703208-0.66-0.66
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:
External ID: IucA Pilot Assay Tocris Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
0.98497.1319127496888TO1A04
1.004100.68831130342TO1A06
1.06110.646227253868TO1A07
1.023104.066889929465TO1A08
1.025104.422529784838TO1A09
1.032105.667269278644TO1A10
1.019103.355610218718TO1A11
1.059110.468407326181TO1A14
1.049108.690208049315TO1A15
1.044107.801108410883TO1A16
1.047108.334568193942TO1A17
1.054109.579307687748TO1A18
1.137124.338361685733TO1A19
1.109119.359403710509TO1A20
1.089115.803005156778TO1A21
1.097117.22556457827TO1A22
0.98998.0210123881216TO1B03
0.98296.7762728943157TO1B04
0.99298.5544721711813TO1B05
1.016102.822150435659TO1B06
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: MTASE-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; SMMTase Enzyme (2x) in reaction buffer, columns 1- 48.
2; Reagent; 1 uL; SAM (4x) in reaction buffer, columns 1-48.
3; Controls; 23 nL; DMSO in column 4; sinefungin in DMSO (0 uM - 40 uM) in 7-point 1:2 dilution series (n = 2) in column 2.
4; Compounds; 23 nL; Columns 5-48.
5; Reagent; 1 uL; Substrate (4x) in reaction buffer, columns 2-48.
6; Time; 20-30 min; Incubation.
7; Reagent; 1 uL; MTase-Glo reagent (5X), columns 1-48.
8; Time; 30 min; Incubation.
9; Reagent; 5 uL; MTase-Glo Detection reagent, columns 1-48.
10; Time; 30 min; Incubation, luminescence evolution.
11; Detection; Luminescence; ViewLux uHTS Microplate Imager (PerkinElmer).

NOTES (numbers refer to Sequence numbers above)
1, 2, 5. White Medium Binding Greiner 1536-well plates (Cat #789175-F, Greiner Bio-One, Monroe, NC); Reaction buffer: 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA. Evaporation was prevented by covering assay plates with metal lids containing holes to allow gas diffusion.
1. Six SMMTase were profiled: HNMT, GNMT, PNMT, COMT, NNMT, GAMT
2. The corresponding SAM cofactor concentration was used for each SMMTase: HNMT - 9.3 uM SAM; GNMT - 12.1 uM SAM; PNMT - 3.6 uM SAM; COMT - 14.5 uM SAM; NNMT 11.9 uM SAM; GAMT - 5.6 uM SAM.
3, 4. Pintool transfer
5. The corresponding substrate was used for each enzyme: HNMT - 5.3 uM Histamine; GNMT - >500 uM Glycine; PNMT - 16.2 uM Norephinephrine; COMT - 13.7 uM Norephinephrine; NNMT - 3.8 uM Nicotinamide; GAMT - 2.5 uM Guanidinoacetate.6, 8, 10. Room temperature
6. Final reaction conditions: 10 nM COMT, 5 uM SAM, 15 uM norepinephrine, 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA; refer to tables 2 and S1 for specific timing.
8. Conversion of SAH to ADP; MTase Glo Kit (Promega, Madison, WI).
10. Conversion of ADP to ATP and detection by UltraGlo luciferase; MTase Glo Kit (Promega, Madison, WI).
11. Settings: 20 s exposure, 1X binning, high gain, medium speed.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are assayed at single point activity (40 uM).
2. Active / Inactive compound calling is based on the results of the enzyme assay panel. ACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 50 and are compounds that have <= -50% max response in ANY ONE of the six enzymes. INACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 0 and are those that have >= -30% max response in ALL SIX enzymes. The remaining compounds are INCONCLUSIVE and have PUBCHEM_ACITIVITY_SCORE = 30.
COMT-Max_ResponseGAMT-Max_ResponseGNMT-Max_ResponseHNMT-Max_ResponseNNMT-Max_ResponsePNMT-Max_Response
-14.477-0.906-64.36-7.723-13.221-6.568
-97.283-96.83-99.246-99.097
-11.662-7.108-69.542-15.105-18.57-11.209
9.957-8.37-63.807-27.029-13.633-0.512
-1.3788.081-1.801-70.001-9.255-2.174
-4.184-8.838-45.186-20.976-17.93-50.762
-64.186-17.487-82.517-23.323-14.889-4.424
-28.27-13.82-44.132-13.042-22.645-61.981
-95.9186.395-70.158.26-8.601-15.867
-6.366.696-61.41910.286-22.134-20.539
2.7649.187-5.281.889-50.6463.945
5.467.241-52.1632.748-5.3684.271
18.645-5.1-85.869-4.46517.42
-33.223-8.861-69.978-8.649-22.429-13.542
-22.681-17.904-81.69-53.866-21.453-18.314
3.649-5.536-6.193-64.526-18.858-7.356
-17.938-19.922-61.7-32.188-41.884-42.419
-0.0336.8778.069-87.187-3.6082.522
66.24812.293-50.945-8.947-3.8437.458
-0.7140.817-11.379-86.711-10.789-2.627
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tyrosine-protein kinase JAK3
External ID: CHEMBL704117
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2000
Volume: 10
Issue: 6
First Page: 575
Last Page: 579
DOI: 10.1016/s0960-894x(00)00051-2

Target ChEMBL ID: CHEMBL2148
ChEMBL Target Name: Tyrosine-protein kinase JAK3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
1000000000IC50<1000000000000nMOutside typical range
79432800000IC50=7.94328234724282E13nMOutside typical range
1000000000IC50<1000000000000nMOutside typical range
1258930000000IC50=1.25892541179417E15nMOutside typical range
316228000000IC50=316227766016838nMOutside typical range
1584890000000IC50=1.58489319246111E15nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: PolK100
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were then added to start the reaction and kinetically read twice at 0 min and 10 min on the Viewlux reader
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0007732774 uMActivity at 0.00163 uMActivity at 0.00369 uMActivity at 0.00818 uMActivity at 0.020 uMActivity at 0.030 uMActivity at 0.047 uMActivity at 0.101 uMActivity at 0.151 uMActivity at 0.243 uMActivity at 0.477 uMActivity at 0.759 uMActivity at 1.287 uMActivity at 2.393 uMActivity at 3.818 uMActivity at 6.336 uMActivity at 11.99 uMActivity at 19.37 uMActivity at 31.37 uMActivity at 60.11 uMActivity at 107.2 uMActivity at 158.4 uMActivity at 229.0 uMCompound QC
Inactive40 0 0 0 01.4694-3.5669-6.2352.85861.80421.4694QC'd by "Chem Div"
Inactive40 0 0 0 0-4.26318.22188.081110.2927-3.9947-4.2631QC'd by "Chem Div"
Inactive40 0 0 0 06.03690.3398-2.1048-8.1695-3.68226.0369QC'd by "Chem Div"
Inactive4-2.05651.7294-3.5894-1.2575-0.5402-2.0565QC'd by "Chem Div"
Inactive40 0 0 0 12.31491.00484.6369-1.9963-3.35432.3149QC'd by "Chem Div"
Inactive47.27487.15156.13721.51975.23327.2748QC'd by "Chem Div"
Inactive40 0 0 0 01.006-3.3873-7.786-9.3037-9.17611.006QC'd by "Chem Div"
Inactive40 0 0 0 0-0.0368-9.4458-10.5155-9.0065-12.9141-0.0368QC'd by "Chem Div"
Inactive40 0 0 0 02.6-7.8084-12.3007-2.0954-6.68872.6QC'd by "Chem Div"
Inactive40 0 0 0 0-11.4867-18.9051-17.4955-19.0735-9.6682-11.4867QC'd by "Chem Div"
Inactive40 0 0 0 0-7.5605-17.2173-11.0038-16.5656-22.4025-7.5605QC'd by "Chem Div"
Inactive4-7.5451-1.1939-1.3084-5.8268-5.3206-7.5451QC'd by "Chem Div"
Inactive40 0 0 0 1-5.5852-4.3753-1.0046-3.1641-10.1524-5.5852QC'd by "Chem Div"
Inactive40 0 0 0 01.1172-6.03917.01189.04461.65331.1172QC'd by "Chem Div"
Inactive42.33591.25181.6626-0.9325-0.91942.3359QC'd by "Chem Div"
Inactive40 0 0 0-19.53540.3984-4.11472.1883-19.5354QC'd by "Chem Div"
Inactive4-5.6552-4.6769-1.9378-0.5867-3.224-5.6552QC'd by "Chem Div"
Inactive4-11.3738-10.4148-13.8912-10.4252-7.8961-11.3738QC'd by "Chem Div"
Inactive4-6.1571-8.7102-2.9113-5.2229-3.4369-6.1571QC'd by "Chem Div"
Inactive40 0 0 0 1-7.3803-8.8177-11.1654-6.5301-15.9483-7.3803QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-2C
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inactive00049.3597000002.228909.3597QC'd by Microsource
Inactive0-4.4754.95490.8748-21.4867440 0 0 0 0 0 0 0-17.07226.10422.829307.402506.12865.2151-17.0722QC'd by Vitas
Inactive0-8.2751.17050.66112-6.66740 0 0 0 0 0 0 0-1.0776-6.3892-2.9698-1.73725.8740.35322.4192.3477-1.0776QC'd by Labotest
Inactive0-4.4254.95490.4933-23.5282-340 0 0 0 0 0 0 0-17.94020.3948-8.1012-10.4184-5.55441.8102-4.77655.7051-17.9402QC'd by Vitas
Inactive000407.8331009.349608.39368.85740QC'd by Sequoia
Inactive000402.13462.08732.87872.198101.071700QC'd by SIGMA
Inactive000406.747707.7196.37060000QC'd by Prestwick
Inactive00041.32598.1273007.30856.14859.763401.3259QC'd by Enzo
Inactive0-6.7754.95490.7871-25.4234-14.789241 0 0 0 0 0 0 1-14.8266-40.4001-18.8558-14.3881-11.9076-28.2695-23.675-23.6904-14.8266QC'd by Microsource
Inactive00040003.22385.382307.503400QC'd by Microsource
Inactive0-4.4754.95490.4377-10.0741240 0 0 0 0 0 0 0-7.9784006.8904-2.128300.76149.8865-7.9784QC'd by Labotest
Inactive0004-2.11844.73944.4107-0.61385.167402.3218-1.3941-2.1184QC'd by Microsource
Inactive000400.23422.97255.131802.023500.05890QC'd by Enzo
Inactive0-8.7250.60.79454.5-11.988640 0 0 0 0 0 0 1-9.0185-8.3238-0.45670.90310.07213.33947.72623.0826-9.0185QC'd by Vitas
Inactive0-9.1254.95490.55695-5.355240 0 0 0 0 0 0 1-2.6103-2.7966.99953.42281.61018.09837.01342.0138-2.6103QC'd by Specs
Inactive00040.9896009.6344004.278600.9896QC'd by GVK
Inactive0-5.5254.0950.6337-3.6963340 0 0 0 0 0 0 0-3.46713.29266.721104.917102.2046-3.4969-3.4671QC'd by Prestwick
Inactive00043.12693.073206.53832.82740-3.41288.31143.1269QC'd by Labotest
Inactive0004002.5786.65920003.36630QC'd by Prestwick
Inactive00042.6761008.9375000.40802.6761QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-9B
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inhibitor0.001595.0131100Complete curve; high efficacy-8.82954.95490.995-92.98592.0272-1.10 0 0 0 0 0 0 0 0 0 0-96.2587-1.6791-84.9271-90.9202-90.8631-90.7375-92.2911-92.6732-94.1019-94.0673-96.0913-96.2587QC'd by SIGMA
Inhibitor0.001796.0144100Complete curve; high efficacy-8.76833.24750.9987-95.37860.6358-1.10 0 0 0 0 0 0 0 0 0 0-96.92941.7123-0.1391-34.4453-93.3159-93.9442-94.1795-94.3745-94.7424-94.9325-95.6129-96.9294QC'd by MedChem Express
Inhibitor0.0017101.1335100Complete curve; high efficacy-8.76834.50450.9988-96.45574.6778-1.10 0 0 0 0 0 0 0 0 0 0-98.62542.93835.3252-23.8352-93.6078-94.3407-94.7755-96.5382-96.9802-98.093-97.488-98.6254QC'd by MedChem Express
Inhibitor0.001495.7664100Complete curve; high efficacy-8.86833.06540.9932-91.73124.0352-1.10 0 0 0 0 0 0 0 0 0 0-94.373606.5073-50.3576-85.2142-89.4583-90.3553-90.6328-93.2878-91.6178-92.6738-94.3736QC'd by MedChem Express
Inhibitor0.002792.056799Complete curve; high efficacy-8.5753.990.9971-93.082-1.0254-1.10 0 0 0 0 0 0 0-97.5703-1.153-56.5542-91.9507-92.331-93.0234-92.9105-92.2466-97.5703QC'd by Alfa Aesar
Inhibitor0.002786.152899Complete curve; high efficacy-8.5754.95490.9984-92.0573-5.9045-1.10 0 0 0 0 0 0 0-92.9872-5.0961-62.3948-91.5014-91.2009-92.0539-90.8793-91.9519-92.9872QC'd by Microsource
Inhibitor0.002198.487899Complete curve; high efficacy-8.6754.50450.9983-91.97956.5083-1.10 0 0 0 0 0 0 0-94.04855.8681-73.3835-89.9758-90.798-91.9458-91.2065-93.7497-94.0485QC'd by Bosche
Inhibitor7.0E-482.733499Complete curve; high efficacy-9.1750.60.8847-82.65670.0767-1.10 0 0 0 0 0 0 0-94.3569-37.5208-62.7186-72.7916-74.3825-79.8918-76.6331-78.5528-94.3569QC'd by Selleck
Inhibitor0.003795.081999Complete curve; high efficacy-8.43621.22210.9994-94.52050.5614-1.10 0 0 0 0 0 0-93.7704-1.16310.6157-11.9264-47.6173-82.383-92.7843-93.7704QC'd by Adooq
Inhibitor0.003394.047999Complete curve; high efficacy-8.47953.51170.9958-93.96230.0856-1.10 0 0 0 0 0 0 0 0 0 0-97.87741.2665-23.1756-88.8678-90.2585-91.8229-92.3997-94.1271-95.2991-93.6757-95.8566-97.8774QC'd by MedChem Express
Inhibitor0.0047102.007598Complete curve; high efficacy-8.32952.24810.997-94.17637.8312-1.10 0 0 0 0 0 0 0 0 0 0-98.71735.6987-9.7434-65.3554-90.638-91.2058-92.371-92.7427-94.2549-94.3053-96.979-98.7173QC'd by GVK
Inhibitor0.0047100.42998Complete curve; high efficacy-8.3253.67720.9994-93.22767.2013-1.10 0 0 0 0 0 0 0-94.74358.1328-8.6557-90.5176-92.1158-93.5383-93.4255-92.4974-94.7435QC'd by Prestwick
Inhibitor0.003896.763498Complete curve; high efficacy-8.4253.990.9994-92.02054.743-1.10 0 0 0 0 0 0 0-93.51674.0536-21.1619-91.8053-91.1174-91.9789-90.7784-91.2901-93.5167QC'd by Selleck
Inhibitor0.004590.539798Complete curve; high efficacy-8.34664.50450.9995-92.4565-1.9167-1.10 0 0 0 0 0 0-93.156-4.128-89.5728-91.2217-93.3904-92.524-93.0057-93.156QC'd by Selleck
Inhibitor0.005298.298798Complete curve; high efficacy-8.2884.95490.9993-92.65815.6406-1.10 0 0 0 0 0 0-93.59410-91.9394-91.381-91.3804-93.5391-93.3571-93.5941QC'd by ChemieTek
Inhibitor0.005298.854698Complete curve; high efficacy-8.2880.60.9861-94.11974.7349-1.10 0 0 0 0 0 0-93.9318-33.6729-64.3585-76.1096-84.2151-92.4038-93.1111-93.9318QC'd by MedChem Express
Inhibitor0.00486.042698Complete curve; high efficacy-8.39924.50450.9996-92.288-6.2454-1.10 0 0 0 0 0 0-91.795-7.0299-86.4668-91.4418-93.2202-92.6549-92.4417-91.795QC'd by Selleck
Inhibitor0.004698.020398Complete curve; high efficacy-8.3383.51170.9996-93.16844.8519-1.10 0 0 0 0 0 0-93.7644-11.8828-91.4502-92.2553-94.1095-92.9439-93.2642-93.7644QC'd by SIGMA
Inhibitor0.0042104.449798Complete curve; high efficacy-8.37954.95490.9968-93.920410.5293-1.10 0 0 0 0 0 0 0 0 0 0-96.62598.66757.5142-90.2575-91.0844-91.1114-92.6871-93.2743-95.4523-94.079-95.5345-96.6259QC'd by BioAustralis
Inhibitor0.004294.942198Complete curve; high efficacy-8.37952.84730.9968-94.75910.183-1.10 0 0 0 0 0 0 0 0 0 0-96.93990.6808-16.1375-78.234-91.1234-91.9081-92.3507-95.4781-97.4887-95.7111-95.4747-96.9399QC'd by ActiveBioChem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_DR-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on drug resistant SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multidrop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.00882.203484Complete curve; high efficacy-8.09921.010.966921.0427103.2462-1.10 0 0 0 0 0 013.188495.474859.067235.842331.665221.923822.070613.1884QC'd by Analyticon
Cytotoxic0.025981.057283Complete curve; high efficacy-7.58624.95490.92316.497297.5544-1.10 0 0 0 0 0 02.512597.003593.26858.94736.670723.420912.53742.5125QC'd by MedChem Express
Cytotoxic0.819985.290183Complete curve; high efficacy-6.08621.75290.99432.3577117.6478-1.10 0 0 0 0 0 034.7953115.2038115.6711122.1398.373449.123231.010634.7953QC'd by Glixx
Cytotoxic0.0190.438383Complete curve; high efficacy-7.99921.06410.985619.9781110.4164-1.10 0 0 0 0 0 013.8267101.704171.224135.805628.627925.082819.478713.8267QC'd by Analyticon
Cytotoxic0.0092105.836183Complete curve; high efficacy-8.03624.0950.998416.204122.0401-1.10 0 0 0 0 0 013.8473120.968928.848618.13117.368317.353714.687813.8473QC'd by SIGMA
Cytotoxic0.468384.095583Complete curve; high efficacy-6.32954.44950.96929.5128113.6083-1.10 0 0 0 0 0 0 0 0 0 021.2667108.9911100.6389111.6185114.5273123.8697121.846750.484436.16335.491326.950121.2667QC'd by MedChem Express
Cytotoxic0.104882.764282Complete curve; high efficacy-6.97951.41630.983812.632295.3964-1.10 0 0 0 0 0 0 0 0 0 010.575588.311793.092698.209696.743461.009638.863620.85115.78315.70359.904810.5755QC'd by BIOMOL
Cytotoxic0.177891.15582Complete curve; high efficacy-6.750.60.967113.9433105.0983-1.10 0 0 0 0 0 09.94996.781688.005652.483744.630729.767723.42539.949QC'd by Waterstone
Cytotoxic0.0106101.825682Complete curve; high efficacy-7.9752.72020.992711.1635112.9891-1.10 0 0 0 0 0 0 010.2995105.5432116.579542.386110.210110.828611.463311.646810.2995QC'd by Prestwick
Cytotoxic0.668497.583882Complete curve; high efficacy-6.1752.33320.990218.8259116.4097-1.10 0 0 0 0 0 0 015.8771121.1891108.6953122.087113.851596.846325.162623.985315.8771QC'd by Enzo
Cytotoxic0.042299.181282Complete curve; high efficacy-7.3751.34430.993310.554109.7352-1.10 0 0 0 0 0 0 010.7613114.3989100.783890.706544.474211.202813.845711.361610.7613QC'd by Tocris
Cytotoxic0.007584.106682Complete curve; high efficacy-8.1254.95490.99839.434493.541-1.10 0 0 0 0 0 0 06.535491.798594.110412.665511.09298.63279.997110.07546.5354QC'd by Bosche
Cytotoxic0.421785.920382Complete curve; high efficacy-6.3750.80.962221.4982107.4185-1.10 0 0 0 0 0 0 016.639100.4185107.3168112.829384.599367.881738.354237.879716.639QC'd by Vitas
Cytotoxic0.145895.744482Complete curve; high efficacy-6.83621.55790.976614.7016110.446-1.10 0 0 0 0 0 04.7392104.3625115.347884.378731.790525.599818.03364.7392QC'd by Microsource
Cytotoxic0.0036107.247382Complete curve; high efficacy-8.4444.95490.99898.6172115.8646-1.10 0 0 0 0 0 07.4398110.64829.223610.03329.4928.91416.32217.4398QC'd by Selleck
Cytotoxic0.163680.294782Complete curve; high efficacy-6.78622.04790.976317.79598.0898-1.10 0 0 0 0 0 06.7352100.462595.567485.02829.253227.68320.08926.7352QC'd by Selleck
Cytotoxic0.023197.640682Complete curve; high efficacy-7.63624.95490.999510.3864108.027-1.10 0 0 0 0 0 010.177107.94198.68449.835111.696111.67178.800110.177QC'd by Selleck
Cytotoxic1.587786.327482Complete curve; high efficacy-5.79921.3310.964223.21109.5374-1.10 0 0 0 0 0 029.2744118.455699.7114104.7412100.992385.097633.922129.2744QC'd by MedChem Express
Cytotoxic0.014689.488582Complete curve; high efficacy-7.83621.28760.99529.344198.8326-1.10 0 0 0 0 0 07.000590.702951.556722.53611.87749.85658.1887.0005QC'd by SynKinase
Cytotoxic0.006596.843182Complete curve; high efficacy-8.18624.0950.99488.9496105.7927-1.10 0 0 0 0 0 03.839102.120912.445311.444810.88219.89667.70273.839QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:15621 靶标:G protein-activated inward rectifier potassium channel 2
External ID: VANDERBILT_HTS_GIRK2_MPD
Protocol: To screen for modulators of the G protein-gated inwardly-rectifying potassium channel subunit 2 (GIRK2) homomeric channels, HEK293 cells were engineered to overexpress GIRK2. These cells were screened using a high-throughput thallium-flux assay in a 384-well format. High-throughput thallium flux assays are based on three principles: (1) extracellular thallium can permeate through potassium channels into cells, (2) the fluorescent dye Thallos enters and stays in the cytoplasm of HEK293 cells, and (3) the fluorescence of Thallos increases dramatically when it interacts with thallium ions. Compounds that modulate the activity of an overexpressed channel, in this case GIRK2, are identified by the change in fluorescence that results from changes in thallium influx into cells through the overexpressed channel.

The screening protocol was conducted as follows. One hour prior to screening, cells were loaded with 1.5 micromolar (muM) Thallos in assay buffer (1x Hank's Balanced Salt Solution and 20 millimolar (mM) HEPES). The liquid handling and imaging was conducted using a kinetic-imaging plate reader, Panoptic (WaveFront Biosciences). Before screening, Thallos-containing buffer was removed from cells and replaced with 20 microliters (muL) per well of assay buffer. Compounds were dissolved in assay buffer at 20 muM. After 8 seconds of imaging, 20 muL of compound solution was added per well and allowed to incubate for 150 seconds. Next, 10 muL of a solution containing 2.0 mM thallium in Base Buffer (125 mM NaHCO3, 1 mM MgSO4, 1.8 mM CaSO4, 5mM Glucose, and 20 mM HEPES) was added to the wells. 30 seconds later, 12 muL of base buffer containing 2.0 mM thallium and 50 mM 2-methyl-2,4-pentanediol (MPD), a partially-activating concentration, was added to each well. MPD has is a previously-described GIRK2 channel activator. Data was collected for 60 seconds after this final addition. The positive control for this screen was 30 muM ivermectin, a natural product previously identified as a GIRK2 activator as part of a small-scale pilot screen. Microsoft Excel was utilized for data analysis. Data were normalized, F/Fo, on a well-to-well basis to account for differences in cell number. Compound activity was analyzed by comparing the sums of control-subtracted amplitudes of fluorescence intensity at 20 seconds after each thallium addition. The top 0.2% compounds corresponding to wells that demonstrated the largest increases in fluorescence were selected as "hits" for counter screening, as described below.

All 63,228 compounds screened using the method described above are listed in column OUTCOME_SCREEN_HITS. The 133 compounds selected as hits based on the above criteria are labelled with "100" in the ACTIVITY column. Fluorescent compounds were included in the inactive compounds and marked with "0" in the ACTIVITY column.

The 133 active compounds from column OUTCOME_SCREEN_HITS were tested for non-specific activity in untransfected HEK293 cells using assay conditions otherwise identical to the primary screen. Column OUTCOME_HEK_COUNTERSCREEN lists the 23 compounds that displayed an increase in fluorescence upon thallium addition with "100" in the ACTIVITY column.

The 110 compounds which were identified as hits in the primary screen but inactive when tested in untransfected HEK293 cells were tested for activity in GIRK2-overexpressing HEK293 cells that did not express NPY4 receptor. Column OUTCOME_GIRK2_COUNTERSCREEN lists the 44 compound that displayed an increase in fluorescence upon thallium addition with "100" in the ACTIVITY column.

The 44 active compounds from column OUTCOME_GIRK2_COUNTERSCREEN were tested at various concentrations to determine if compound activity was concentration dependent. Column OUTCOME_GIRK2_DOSE_RESPONSE provides the efficacy of these compounds; activity of all compounds at the provided concentrations was normalized to the activity of VU0537695 at 25 muM, which was the highest efficacy observed during this screening. For each compound concentration listed, the efficacy of that compound provided refers to the normalized, control-subtracted fluorescence intensity at 15 seconds after the addition of thallium. The 28 compounds that demonstrated >5% efficacy and concentration-dependent activity were labelled as "100" in the ACTIVITY column.

Finally, column PUBCHEM_ACTIVITY_OUTCOME combines all of the information from the above counterscreens together, indicating the 28 hits from this GIRK2 screen.
Comment:
OUTCOME_SCREEN_HITSOUTCOME_HEK_COUNTERSCREENOUTCOME_GIRK2_COUNTERSCREENOUTCOME_GIRK2_DOSE_RESPONSE% Efficacy @ 25uM% Efficacy @ 8.3uM% Efficacy @ 2.8uM% Efficacy @ 0.94uM% Efficacy @ 0.15uM% Efficacy @ 0.024uM
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
INACTIVE
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_N-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on naive SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multi-drop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.016689.527684Complete curve; high efficacy-7.77952.09370.944225.8586115.3863-1.10 0 0 0 0 0 0 0 0 0 05.6755108.6505117.9375108.116652.745348.993823.989228.850825.686529.035727.31935.6755QC'd by MedChem Express
Cytotoxic0.0281.223183Complete curve; high efficacy-7.69920.80.972316.819798.0429-1.10 0 0 0 0 0 08.45590.219374.545244.291328.140927.05921.55068.455QC'd by Analyticon
Cytotoxic0.032686.593783Complete curve; high efficacy-7.48620.70.95318.8792105.4729-1.10 0 0 0 0 0 08.453296.808473.066745.439734.552529.766627.43068.4532QC'd by MedChem Express
Cytotoxic0.01683.312682Complete curve; high efficacy-7.79644.95490.99689.607592.9201-1.10 0 0 0 0 0 0 09.777389.297696.418711.99539.71678.86779.754210.35039.7773QC'd by LightBiologicals
Cytotoxic0.010694.295182Complete curve; high efficacy-7.9753.1320.995511.6947105.9898-1.10 0 0 0 0 0 0 011.6947100.9198109.394435.824211.756910.793412.383613.314511.6947QC'd by Prestwick
Cytotoxic0.002788.975382Complete curve; high efficacy-8.5754.95490.99928.907497.8826-1.10 0 0 0 0 0 0 06.903497.991442.29369.96869.10388.22179.30529.09336.9034QC'd by Alfa Aesar
Cytotoxic0.008480.513982Complete curve; high efficacy-8.0754.95490.99738.893889.4076-1.10 0 0 0 0 0 0 06.357787.157291.349912.957111.042110.34028.91169.86186.3577QC'd by Bosche
Cytotoxic0.005197.54282Complete curve; high efficacy-8.2944.50450.99928.7153106.2574-1.10 0 0 0 0 0 07.9842105.047213.76299.49049.84647.65467.1497.9842QC'd by Selleck
Cytotoxic0.020694.499882Complete curve; high efficacy-7.68624.0950.998411.2634105.7632-1.10 0 0 0 0 0 010.8677105.387387.541714.414211.97659.14619.209710.8677QC'd by Selleck
Cytotoxic0.461193.529282Complete curve; high efficacy-6.33621.46410.963718.0367111.5659-1.10 0 0 0 0 0 06.0375113.1729110.6758104.027672.57924.333235.37316.0375QC'd by ChemieTek
Cytotoxic0.025983.407982Complete curve; high efficacy-7.58621.17050.994210.379993.7878-1.10 0 0 0 0 0 05.519287.484466.342228.540116.433812.144911.87075.5192QC'd by MedChem Express
Cytotoxic0.020680.277982Complete curve; high efficacy-7.68623.67720.970514.587194.865-1.10 0 0 0 0 0 07.291596.26274.959527.541914.606313.184910.65757.2915QC'd by MedChem Express
Cytotoxic0.025999.996582Complete curve; high efficacy-7.58621.11050.962710.993110.9895-1.10 0 0 0 0 0 03.5224101.819278.672730.344220.104225.11194.47963.5224QC'd by APExBIO
Cytotoxic0.014690.789582Complete curve; high efficacy-7.83621.34370.9969.109499.8989-1.10 0 0 0 0 0 06.212391.419653.831819.277613.66628.56187.43726.2123QC'd by APExBIO
Cytotoxic0.651381.720382Complete curve; high efficacy-6.18621.47870.989621.402103.1224-1.10 0 0 0 0 0 021.0506108.908195.7413101.202878.035734.663424.989321.0506QC'd by Glixx
Cytotoxic0.01384.007482Complete curve; high efficacy-7.88621.41630.994410.069994.0773-1.10 0 0 0 0 0 05.978686.088247.355717.899613.582410.519910.4225.9786QC'd by MedChem Express
Cytotoxic0.08285.068682Complete curve; high efficacy-7.08620.910.991514.09999.1676-1.10 0 0 0 0 0 010.217194.606584.923959.808127.552123.690516.789310.2171QC'd by Glixx
Cytotoxic0.006584.635382Complete curve; high efficacy-8.18624.0950.99828.850193.4854-1.10 0 0 0 0 0 06.501790.372511.997510.293910.1119.52798.25216.5017QC'd by APExBIO
Cytotoxic0.00982.724382Complete curve; high efficacy-8.0441.28760.991710.51293.2363-1.10 0 0 0 0 0 07.734485.514346.479122.47513.19099.748711.73337.7344QC'd by MedChem Express
Cytotoxic4.0E-494.19682Complete curve; high efficacy-9.3752.40640.99887.7324101.9284-1.10 0 0 0 0 0 07.3587100.769474.71979.88399.60588.64768.49037.3587QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NTMT1-p-MTaseGlo
Protocol: Materials: NTMT1 enzyme, substrate SPKRIA, control peptide RCC1-6 is provided by the Huang laboratory.

MTaseGlo Assay:
PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; Enzyme; 3 uL; Dispense enzyme mixture (final concentrations of 125 nM NTMT1 and 100 uM SAM) into Greiner 1536-well white / solid bottom assay plate (Greiner Bio One, Monroe, NC).
2; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array (Wako Automation, Richmond, VA)
3; Incubation; 15 min; Incubate at room temperature
4; Substrate; 1 uL; Dispense 1 uL of substrate at final concentration of 1 uM. Buffer solution was dispensed in control wells. The assay plate was covered with metal lids.
5; Incubation; 30 min; Incubate at room temperature, protected from lights.
6; Reagent; 1 uL; Dispensed 5x MTase-Glo detection reagent (R) into the assay plate. The plate was covered with metal lids.
7; Incubation; 30 min; Incubate the assay plates at room temperature in the dark to allow for SAH to be converted to ADP.
8; Reagent; 5 uL; Dispense 5 uL of 1x MTase-Glo Detection Solution (R) to allow for ADP to be converted to ATP which was then detected with a luciferase reaction.
9; Centrifuge; 15 sec; Centrifuge the assay plate for 15 seconds at 1000 RPM.
10; Incubation; 30 min; Assay plates were incubation at room temperature in the dark.
11; Detection; Luminescence; Plates were read on ViewLux detector (PerkinElmer). Data were normalized to no-enzyme (0% activity) and no-inhibitor (DMSO; 100%) controls, and the resulting percent inhibition data were fitted to a 4-parameter Hill equation using GraphPad Prism.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000420468 uMActivity at 0.0001060182 uMActivity at 0.0001893301 uMActivity at 0.0004489405 uMActivity at 0.0009664426 uMActivity at 0.00171 uMActivity at 0.00292 uMActivity at 0.00536 uMActivity at 0.00931 uMActivity at 0.020 uMActivity at 0.041 uMActivity at 0.085 uMActivity at 0.146 uMActivity at 0.251 uMActivity at 0.501 uMActivity at 1.073 uMActivity at 2.225 uMActivity at 4.221 uMActivity at 6.452 uMActivity at 12.64 uMActivity at 29.84 uMActivity at 57.50 uMActivity at 114.0 uMActivity at 227.6 uMActivity at 379.2 uMActivity at 573.0 uMCompound QC
Inactive0004-8.3336-1.4117-0.6141-1.80790.0446-8.3336QC'd by Sytravon
Inactive0-5.754.95490.364-29.48243.380540 0 0 0 1-1.39543.25350.7839-59.13736.0E-4-1.3954QC'd by Sytravon
Inactive0-6.753.1320.78430.870212.540 0 0 0 04.496310.2975-0.4426-1.35820.16264.4963QC'd by Sytravon
Inactive00042.0548-1.7066-2.8833-2.0050.36932.0548QC'd by Sytravon
Inactive0004-5.64220.4339-3.0268-4.4255-2.8516-5.6422QC'd by Sytravon
Inactive00040.2315-0.9193-0.962513.7196-1.97040.2315QC'd by Sytravon
Inactive0-5.054.95490.5023-0.05257.540 0 0 0 15.3132.711112.72021.5451-0.04385.313QC'd by Sytravon
Inactive00044.3883-3.3207-0.3808-0.1461-2.9714.3883QC'd by Sytravon
Inactive00045.7635-0.6995-1.72946.10241.83175.7635QC'd by Sytravon
Inactive0-4.31.06930.8616-4.25739.540 0 0 0 0-1.881111.14848.55025.98854.608-1.8811QC'd by Sytravon
Inactive0004-1.7273-3.4115-0.1881-2.6331-1.6916-1.7273QC'd by Sytravon
Inactive00044.3895-3.0627-1.10014.78020.86424.3895QC'd by Sytravon
Inactive0-54.95490.664910.50.702140 0 0 0 013.78374.4863-3.58167.22047.367813.7837QC'd by Sytravon
Inactive00046.01793.3436.89312.29364.52246.0179QC'd by Sytravon
Inactive000411.32073.08785.1642.55725.361511.3207QC'd by Sytravon
Inactive00048.73833.26642.73073.24051.84638.7383QC'd by Sytravon
Inactive0-4.052.72020.9497-18.9142-2.292240 0 0 0 0-14.0952-1.0768-4.0059-2.4795-5.6228-14.0952QC'd by Sytravon
Inactive0004-7.7765-2.2569-3.9959-1.34510.1566-7.7765QC'd by Sytravon
Inactive0-44.95490.7054-25.0658-0.540 0 0 0 0-17.5549-2.6051-3.8192-2.69936.0774-17.5549QC'd by Sytravon
Inactive0-5.84.95490.4109-5.3905440 0 0 0 0-2.49043.8042.4492-14.07540.8551-2.4904QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR001
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inactive000406.942202.372800.458305.80229.8216000QC'd by BIOMOL
Inactive00040000.78791.0771004.091704.998300QC'd by BIOMOL
Inactive0-7.37924.95490.41460.86115.540 0 0 0 0 0 0 0 0 0 01.837309.11175.53448.2389002.305104.4881-0.94911.8373QC'd by BIOMOL
Inactive0-5.17922.72020.8215-20.66392.540 0 0 0 0 0 0 0 0 0 1-6.09160-2.79660.22858.08152.5833.73547.32021.7166-5.5554-18.8865-6.0916QC'd by BIOMOL
Inactive00043.74957.22936.37145.613507.482901.69948.4113003.7495QC'd by BIOMOL
Inactive00046.36577.19537.3079001.87945.979907.4799006.3657QC'd by BIOMOL
Inhibitor14.81835.514921Partial curve; partial efficacy-4.82923.06540.9214-31.01494.5-2.20 0 0 0 0 0 0 0 0 0 0-30.42915.77728.87813.66834.2274.72228.01864.5719-4.21873.6532-13.8256-30.4291QC'd by BIOMOL
Inactive000405.78175.8939008.5995006.074406.5850QC'd by BIOMOL
Inactive0004-2.104508.25230-2.17247.221607.3601-2.8223-6.14464.4899-2.1045QC'd by BIOMOL
Inactive0-4.42924.95490.4721-18.4451.540 0 0 0 0 0 0 0 0 0 0-13.287507.01614.53755.0482005.2422-2.8732-8.90186.1541-13.2875QC'd by BIOMOL
Inactive00049.43850000.93210.52520009.489409.4385QC'd by BIOMOL
Inactive0004-1.189406.558504.48600.538104.86393.46642.4738-1.1894QC'd by BIOMOL
Inactive0-6.07924.95490.40475.50.155340 0 0 0 0 0 0 0 0 0 101.4724.5108000-2.787208.386408.06150QC'd by BIOMOL
Inactive0004000.71730.66792.56178.0704009.810508.97310QC'd by BIOMOL
Inactive00041.1339-2.329408.3935009.78267.57146.4163001.1339QC'd by BIOMOL
Inactive0-9.02924.95490.38982-12.787140 0 0 0 0 0 0 0 0 0 1-4.0609-8.98923.4212-1.75787.17160.61375.21776.7693.1957-7.1191-0.2144-4.0609QC'd by BIOMOL
Inhibitor20.931101.63441Partial curve; high efficacy-4.67924.0950.99-99.56492.069-2.10 0 0 0 0 0 0 0 0 0 0-91.68045.251107.629403.87461.2696000-20.7764-91.6804QC'd by BIOMOL
Inactive000402.320402.28163.4121.25641.61620000.22870QC'd by BIOMOL
Inactive0-4.57924.50450.7778-24.88853.540 0 0 0 0 0 0 0 0 0 0-22.82385.74268.64626.02173.77214.16569.06293.0606-1.1003-6.03351.2279-22.8238QC'd by BIOMOL
Inhibitor33.1734109.831210Single point of activity-4.47924.95490.9783-109.32610.505-30 0 0 0 0 0 0 0 0 0 0-91.5629-0.0109-1.05751.09492.26989.4465-3.45940-7.435400-91.5629QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR002
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inhibitor4.109535.955421Complete curve; partial efficacy-5.38621.47870.9847-33.45542.5-1.20 0 0 0 0 0 0-32.46282.18335.970600-5.6126-25.295-32.4628QC'd by Axon Medchem
Inhibitor14.58134.657110Partial curve; partial efficacy; poor fit-4.83622.33320.9403-32.15712.5-2.40 0 0 0 0 0 0-29.71430007.41155.8195-6.9018-29.7143QC'd by Tocris
Inactive0-4.83621.86170.9256-16.65942.540 0 0 0 0 0 0-14.71612.62120.581.02516.28291.7864-3.3449-14.7161QC'd by Glixx
Inhibitor1.63666.161564Complete curve; partial efficacy-5.78622.72020.9997-65.81160.3499-1.20 0 0 0 0 0 0-66.50140000-37.9408-64.7373-66.5014QC'd by Glixx
Inactive0-4.63621.96730.7584-23.667-2.467140 0 0 0 0 0 0-19.3058-0.694-0.3893-3.2758-10.1148-2.3842-5.3061-19.3058QC'd by SIGMA
Inactive0-4.78623.06541-20.0675040 0 0 0 0 0 0-19.222900000-2.9492-19.2229QC'd by Axon Medchem
Inhibitor10.322547.836221Partial curve; partial efficacy-4.98621.88510.9724-41.83626-2.20 0 0 0 0 0 0-38.7819.20936.095507.71415.1385-14.8631-38.781QC'd by MedChem Express
Inactive00046.01782.42486.41361.896906.213206.0178QC'd by Tocris
Inhibitor29.092960.09310Single point of activity-4.53624.95491-60.03460.0584-30 0 0 0 0 0 0-54.4164000000-54.4164QC'd by Tocris
Inactive0004-6.543200000-1.4393-6.5432QC'd by Tocris
Inhibitor16.360136.851110Partial curve; partial efficacy; poor fit-4.78621.010.8986-32.35114.5-2.40 0 0 0 0 0 0-23.62598.789708.696100-7.2303-23.6259QC'd by Tocris
Inactive00049.2406001.75143.496707.9269.2406QC'd by Glixx
Inhibitor9.233.715210Partial curve; partial efficacy; poor fit-5.03621.41630.9706-30.21523.5-2.40 0 0 0 0 0 0-27.26265.31472.675106.30420-12.9935-27.2626QC'd by Tocris
Inhibitor16.360152.695221Partial curve; partial efficacy-4.78621.28760.9602-49.04213.653-2.20 0 0 0 0 0 0-37.79029.1493005.18520-13.7877-37.7902QC'd by Tocris
Inactive0-4.78624.44950.9565-27.1196340 1 0 0 0 0 0-26.76640-80.85495.97525.378600.9575-26.7664QC'd by Tocris
Inhibitor0.580574.818526Complete curve; partial efficacy-6.23623.67720.9839-72.75452.064-1.20 0 0 0 0 0 0-64.73751.50932.14072.7381-9.5317-70.5587-81.6221-64.7375QC'd by MedChem Express
Inhibitor18.356499.324110Single point of activity-4.73623.62720.9917-97.78141.5427-30 0 0 0 0 0 0-94.201708.64420-1.04460-6.3447-94.2017QC'd by Tocris
Inhibitor29.092985.830210Single point of activity-4.53624.95490.9979-84.3311.4991-30 0 0 0 0 0 0-76.60620.5645002.14332.14953.4024-76.6062QC'd by MedChem Express
Inhibitor12.995349.172121Partial curve; partial efficacy-4.88622.25260.9678-45.67253.4996-2.20 0 0 0 0 0 0-42.17617.83150.28501.26966.3138-12.2728-42.1761QC'd by Tocris
Inactive0-4.68621.88510.8683-38.0965-12.016740 0 0 0 0 0 0-33.4065-7.5139-13.5025-14.684-16.035-8.8732-16.7676-33.4065QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:BindingDB 靶标:N/A
External ID: BindingDB_5103_1
Protocol: N/A
Comment: Compounds with any of Ki, IC50, Kd, or EC50 activity value <= 10uM are labeled as "Active".
If multiple measurements are available for a given compound, it is labeled as "Active" if any of the measurements meet the criterion. Activity values are checked in the order of Ki, IC50, Kd, and EC50. The first entry that meets the above activity threshold is used to determine "Standard Type", "Standard Relation", and "PubChem Standard Value". Otherwise, the first non-empty entry will be used to set those values.
Standard TypePubChem Standard ValueKiTarget Accession(s)LigandTarget
Ki27.127100P00547BDBM85123Homoserine kinase
Ki0.46460P00547BDBM85124Homoserine kinase
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2mCherry
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral ininfection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times postinfection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.53 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.39870.9996-13.0836-0.585340 0 0 1-0.8016-2.9877-9.467-12.5697-0.8016QC'd by "Asinex Ltd."
Inhibitor12.589340.511110Single point of activity-4.94.50450.9991-45.3562-4.8451-30 0 0 0-45.0493-5.3378-3.9936-8.2693-45.0493QC'd by "Asinex Ltd."
Inactive040-2.0352000QC'd by "Asinex Ltd."
Inactive04000-0.99410QC'd by "Asinex Ltd."
Inactive04.954910-13.633540 0 0 00-12.1946000QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive04-13.3369-12.1444-5.0835-13.8274-13.3369QC'd by "Asinex Ltd."
Inactive040-4.5112-3.956800QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive01.80790.9998-19.4131.540 0 0 1-2.29920-11.3763-18.6775-2.2992QC'd by "Asinex Ltd."
Inactive04.95490.77214-15.639840 0 0 00-10.469-15.9421-20.94990QC'd by "Asinex Ltd."
Inactive04.95490.9987-20.1455-0.540 0 0 0-19.28790-0.8113-0.6866-19.2879QC'd by "Asinex Ltd."
Inactive04.95490.9999-7.3207040 0 0 0-6.934000-6.934QC'd by "Asinex Ltd."
Inactive04-10.13410-23.8022-3.1543-10.1341QC'd by "Asinex Ltd."
Inactive01.82650.9999-31.5926140 0 0 1-8.44790-12.323-29.2439-8.4479QC'd by "Asinex Ltd."
Inactive00.70.95422-18.098140 0 0 00-15.9151-9.0083-6.24390QC'd by "Asinex Ltd."
Inactive04.95490.79940.5884-8.240 0 0 0-1.1763-9.1365-5.7126-9.75-1.1763QC'd by "Asinex Ltd."
Inactive00.60.9653-16.23140.75640 0 0 0-14.3595-3.5367-8.6422-10.5182-14.3595QC'd by "Asinex Ltd."
Inactive04-3.3063-1.5829-0.45720-3.3063QC'd by "Asinex Ltd."
Inactive04.95490.7973-6.6878-1.540 0 0 10-2.54350-5.57310QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495583
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
1.33IC50=1330nMDtt Insensitive
0.39IC50=390nMDtt Insensitive
1.6IC50=1600nMDtt Insensitive
0.14IC50=140nMDtt Insensitive
2.8IC50=2800nMDtt Insensitive
0.39IC50=390nMDtt Insensitive
1.58IC50=1580nMDtt Insensitive
0.03IC50=30nMDtt Insensitive
3.99IC50=3990nMDtt Insensitive
0.36IC50=360nMDtt Insensitive
0.22IC50=220nMDtt Insensitive
1.37IC50=1370nMDtt Insensitive
0.22IC50=220nMDtt Insensitive
0.4IC50=400nMDtt Insensitive
4.58IC50=4580nMDtt Insensitive
4.38IC50=4380nMDtt Insensitive
0.19IC50=190nMDtt Insensitive
1.74IC50=1740nMDtt Insensitive
3.86IC50=3860nMDtt Insensitive
0.05IC50=50nMDtt Insensitive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NAD-dependent protein deacetylase sirtuin-2
External ID: CHEMBL913334
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2006
Volume: 49
Issue: 25
First Page: 7307
Last Page: 7316
DOI: 10.1021/jm060118b

Target ChEMBL ID: CHEMBL4462
ChEMBL Target Name: NAD-dependent deacetylase sirtuin 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition>60%
Inhibition>60%
Inhibition>60%
Inhibition>60%
Inhibition>60%
Inhibition>60%
Inhibition>60%
Inhibition>60%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2Venus
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral infection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times post-infection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.52 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.46410.71-12.454-240 0 0 0-11.2117-5.20930.6206-7.2594-11.2117QC'd by "Chem Div"
Inactive04-11.3429-16.0267-12.2608-14.6132-11.3429QC'd by "Chem Div"
Inactive01.62590.9272-14.3148-0.87740 0 0 0-15.2623-7.8142-13.6096-13.0621-15.2623QC'd by "Chem Div"
Inactive04-12.3142-9.814-12.586-8.4662-12.3142QC'd by "Chem Div"
Inactive04-8.2677-9.1999-12.2836-11.2753-8.2677QC'd by "Chem Div"
Inactive04.50450.9238-23.3577-9.005740 0 0 0-23.2147-6.6714-11.5717-9.7492-23.2147QC'd by "Chem Div"
Inhibitor11.220218.895721Partial curve; partial efficacy-4.953.51170.9065-31.7758-12.8801-2.20 0 0 0-31.4798-16.0985-9.0667-16.5103-31.4798QC'd by "Chem Div"
Inactive04.95490.8003-13.5254-8.878340 0 0 0-13.3545-10.4528-7.3986-12.9731-13.3545QC'd by "Chem Div"
Inactive02.33320.9015-5.5393840 0 0 0-5.44945.481810.30710-5.4494QC'd by "Chem Div"
Inactive01.96730.9741-21.6735-12.493740 0 0 0-21.3946-13.4008-12.078-16.6303-21.3946QC'd by "Chem Div"
Inactive04-5.6419-17.3934-2.7552-14.5706-5.6419QC'd by "Chem Div"
Inactive04.95490.8944-16.0102-8.684840 0 0 0-15.0085-7.2373-9.9603-8.6791-15.0085QC'd by "Chem Div"
Inactive01.55790.9997-19.5854-2.051340 0 0 1-5.8527-2.9594-9.4187-17.9878-5.8527QC'd by "Chem Div"
Inactive00.90.997418-20.238340 0 0 012.7737-17.6986-10.21151.105512.7737QC'd by "Chem Div"
Inactive01.88510.9998-14.291-6.778340 0 0 1-6.726-6.8986-8.4505-13.1591-6.726QC'd by "Chem Div"
Inactive00.90.9901-24.8053-6.556940 0 0 0-19.0044-6.7141-9.2211-12.2131-19.0044QC'd by "Chem Div"
Inhibitor1025.752521Partial curve; partial efficacy-54.95490.9958-34.5683-8.8157-2.20 0 0 0-34.709-9.7184-7.7631-13.3604-34.709QC'd by "Chem Div"
Inactive00.50.7446-13.2445-2.110940 0 0 0-9.3704-2.5924-6.2168-4.8236-9.3704QC'd by "Chem Div"
Inactive04.95490.8017-7.4285-18.016840 0 0 0-7.4434-13.764-5.7738-9.5578-7.4434QC'd by "Chem Div"
Activator31.6228490Partial curve; high efficacy-4.50.80.9998651142.10 0 0 1118.3965112.9568110.0983102.4909118.3965QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495585
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4295557
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Inhibition=17%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=47%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=0%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=8%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=47%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=10%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=16%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=14%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=34%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=9%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=5%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=24%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=3%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=0%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=0%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=0%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=19%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=48%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=0%% Inhibition At 10Um Mers 3Cl-Pro
Inhibition=26%% Inhibition At 10Um Mers 3Cl-Pro
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495584
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4295557
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
26.8IC50=26800nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
10IC50>10000nMIc50 Mers 3Cl-Pro
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: APP-Toga-CHIKV-nsP2-f2-f9
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1.Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2.Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3.The plate was incubated at room temperature (protected from light) for 15 min
4.Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5.After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1.Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2.For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001943322 uMActivity at 0.0004169086 uMActivity at 0.0006184621 uMActivity at 0.00125 uMActivity at 0.00187 uMActivity at 0.00374 uMActivity at 0.00620 uMActivity at 0.011 uMActivity at 0.019 uMActivity at 0.034 uMActivity at 0.057 uMActivity at 0.103 uMActivity at 0.171 uMActivity at 0.309 uMActivity at 0.513 uMActivity at 0.958 uMActivity at 1.860 uMActivity at 2.874 uMActivity at 5.579 uMActivity at 8.623 uMActivity at 16.74 uMActivity at 25.51 uMActivity at 50.00 uMActivity at 83.33 uMActivity at 250.0 uMCompound QC
Inactive0004-3.9794-0.1198-7.062-11.5818-9.1944-3.8178-1.1441-5.6132-4.9511-5.5587-6.1624-3.9794QC'd by ACC
Inactive0-8.19790.30.608993140 0 0 0 0 0 0 0 0 0 010.172223.924224.655819.16521.660312.625318.76147.470919.892413.78158.189910.1722QC'd by Pharmaron
Activator8.955243.2190Partial curve; partial efficacy; poor fit-5.04791.3310.924736.0289-7.19012.40 0 0 0 0 0 0 0 0 0 029.4662-7.0776-6.47-9.2528-8.4641-9.2431-10.5751-5.22763.4595-2.881113.357829.4662QC'd by SIGMA
Inactive0-5.24790.40.3288-23.185-14.612940 0 0 0 0 0 0 0 0 0 0-20.7246-17.2155-15.3616-10.5108-18.084-14.0374-14.4678-15.7745-20.1988-20.9875-15.4123-20.7246QC'd by SIGMA
Activator7.113361.86540Partial curve; partial efficacy-5.14791.22210.985957.5474-4.3182.20 0 0 0 0 0 0 0 0 0 047.1053-2.7798-7.765-4.3513-5.9053-6.2870.5579-3.14590.608510.477728.702947.1053QC'd by Microsource
Inactive0-4.99790.60.627332840 0 0 0 0 0 0 0 0 0 026.108311.84129.28933.73345.70737.117815.20258.219319.316410.390817.592726.1083QC'd by Sequoia
Inactive0-5.74792.84730.9367-8.457912.540 0 0 0 0 0 0 0 0 0 0-9.131617.489614.59513.712112.150311.963210.01038.353810.3971-3.7628-7.349-9.1316QC'd by SIGMA
Inactive0-6.19790.60.544812-8.077540 0 0 0 0 0 0 0 0 0 1-5.6385-0.4717-21.3146-4.9131-1.5492-3.8745-4.9958-1.24894.18266.38268.2921-5.6385QC'd by Sytravon
Activator0.2832102.74350Partial curve; high efficacy-6.54791.78850.9885108.743562.10 0 0 0 0 0 0 0 1 1 1-95.91469.03367.02688.00912.495715.738721.831160.2571100.6884-22.8645-96.4497-95.9146QC'd by Sytravon
Inactive0-7.24790.50.705816240 0 0 0 0 0 0 0 0 0 17.40721.81285.59638.76350.293110.41188.75414.272511.851314.558914.81967.4072QC'd by Sytravon
Inactive0-6.09792.33320.5919-23.922-17.424240 0 0 0 0 0 0 0 0 0 0-24.9757-19.9067-14.6333-19.3926-16.8611-18.3099-13.2702-19.0908-20.4306-26.6017-20.1209-24.9757QC'd by Selleck
Activator2.523937.05290Partial curve; partial efficacy-5.59791.10.889926-11.05292.20 0 0 0 0 0 0 0 0 0 1-9.5741-14.2107-9.4787-6.7894-9.9383-13.1553-12.9138-4.80511.47322.279422.5785-9.5741QC'd by MedChem Express
Inactive0004-13.8524-9.282-5.697-4.2734-5.2179-3.3835-12.0959-4.84792.5228-14.939-6.0319-13.8524QC'd by Analyticon
Inactive0-5.65921.71370.8905-25.7583-14.342340 0 0 0 0 0 0 0 0 0 0-25.6319-16.1698-13.0793-14.8397-14.8495-13.9732-15.8115-12.3686-13.1319-19.083-21.7489-25.6319QC'd by Analyticon
Inactive0-7.50924.95490.619722.51340 0 0 0 0 0 0 0 0 0 19.598319.80839.92213.466214.199812.236423.007719.385826.190324.596918.43779.5983QC'd by Analyticon
Inactive0-7.84791.82650.8442-13.182-2.534240 0 0 0 0 0 0 0 0 0 0-17.235-1.6952-2.6747-4.1488-5.954-12.7639-12.1446-11.8915-10.8594-10.5634-16.1912-17.235QC'd by Analyticon
Inactive0004-17.7491-20.0995-21.9281-15.9595-15.8056-19.8756-17.2058-20.6448-14.277-20.5571-18.9876-17.7491QC'd by MedChem Express
Inactive0-6.44790.40.90323818.540 0 0 0 0 0 0 0 1 1 11.046919.221819.961723.310422.263624.416123.653128.414430.579620.197211.55121.0469QC'd by MedChem Express
Inactive0-5.25922.47290.682-17.827616.540 0 0 0 0 0 0 0 0 0 0-13.815121.03812.38782.682312.39217.096620.565119.339528.679215.0074.7718-13.8151QC'd by Analyticon
Inactive0-5.34791.10.676-42.4703-22.027640 0 0 0 0 0 0 0 0 0 0-37.2303-24.1889-23.1958-17.9964-27.2599-16.273-18.493-30.4886-23.3633-27.5267-38.9926-37.2303QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Histone deacetylase 6
External ID: CHEMBL4808149
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL1865
ChEMBL Target Name: Histone deacetylase 6
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: Fraunhofer Institute HDAC6 screening
Standard TypeStandard RelationStandard ValueStandard Text ValueStandard UnitsData Validity Comment
Inhibition=-13.63%Outside typical range
Inhibition=-37.85%Outside typical range
Inhibition=-31.68%Outside typical range
Inhibition=-40.84%Outside typical range
Inhibition=-33.51%Outside typical range
Inhibition=-11.71%Outside typical range
Inhibition=-12.48%Outside typical range
Inhibition=8.75%
Inhibition=-57.22%Outside typical range
Inhibition=-43.91%Outside typical range
Inhibition=-42.06%Outside typical range
Inhibition=25.26%
Inhibition=31.78%
Inhibition=-63.83%Outside typical range
Inhibition=1.14%
Inhibition=-17.63%Outside typical range
Inhibition=14.49%
Inhibition=3.28%
Inhibition=10.08%
Inhibition=13.93%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f3_f16
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1a; Reagent; 3 uL; Papain in assay buffer.
1b; Reagent; 3uL; Assay buffer
2; Compound; 17 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 1 uL; Z-FR-AMC in assay buffer.
5; Incubation; 15 sec, 271g; centrifugation.
6; Detection; Fluorescence; time 0, Viewlux microplate reader (PerkinElmer) 355 nm excitation, 460 nm emission
7; Incubation; 10 min; room temperature
8; Detection; Fluorescence; time 10; ViewLux microplate reader (PerkinElmer), 355 nm excitation, 460 nm emission.

NOTES (numbers refer to sequence numbers above).
1a. Medium-binding black solid-bottom Greiner plates (cat. 789176-F). Dispense 3 uL of 1.33X papain in assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 1, 2, 5-48 via Wako/Kalypsys dispenser. Papain (cat. P4762, Sigma) was dispensed to produce 5 nM final concentration. Enzyme solution kept on ice during experiment. Prepare papain as 50% glycerol (v/v) at final concentration of 10 mg/mL (427 uM, 100 U/mL). Sources: microplates (Greiner 789176-F), papain (Sigma P4762), sodium acetate (Bioworld 40120009-2), cysteine (Sigma 861677), Tween-20 (Sigma P1379), water (GIBCO 10977-015; Gibco).
1b. Dispense 3 uL of assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 3 and 4 via Wako/Kalypsys dispenser. Assay buffer solution kept on ice during experiment.
2. Compound addition by single pin transfer (17 nL) using Wako pintool. Compound solutions in source plate: 169 nM to 10 mM DMSO stock solutions. Final concentrations: 0.664 nM to 39.2 uM, respectively. Final DMSO concentration: 0.5% (v/v).
3. RT incubation. Kalypsys lids used as microplate coverings. Protected from light.
4. Dispense 1 uL of 4x substrate mixture in assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 1-48 via Wako/Kalypsys dispenser. Z-FR-AMC substrate was dispensed to produce 2 uM final concentration. Substrate solution kept on ice during experiment. Prepare Z-FR-AMC as 32.1 mM stock solution in DMSO. Source: Z-FR-AMC (HCl salt) (Bachem I-1160).
5. Centrifugation step to remove bubbles.
6. ViewLux microplate reader (PerkinElmer, Waltham, MA). Optics: excitation filter 340 (30) nm, emission filter 450 (20) nm. Energy = 2000. Exposure time = 2 sec.
7. RT incubation. Incubation time 10 min.
8. ViewLux microplate reader. Optics: excitation filter 340 (30) nm, emission filter 450 (20) nm. Energy = 2000. Exposure time = 2 sec.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008338173 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00749 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.114 uMActivity at 0.206 uMActivity at 0.342 uMActivity at 0.619 uMActivity at 1.026 uMActivity at 1.916 uMActivity at 3.719 uMActivity at 5.749 uMActivity at 11.16 uMActivity at 17.25 uMActivity at 33.47 uMActivity at 51.01 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor2.5901109.960786Complete curve; high efficacy-5.58671.210.9897-108.96071-1.10 0 0 0 0 0 0 0 0 0 0-111.41171.55560.16860.5912-2.32080.5546-1.7222-9.4735-49.3194-78.617-90.0782-111.4117QC'd by Tocris
Inhibitor2.057490.645386Complete curve; high efficacy-5.686710.9996-95.4556-4.8103-1.10 0 0 0 0 0 0 0 0 0 0-91.4326-5.6107-5.4875-5.5173-5.2586-8.3832-11.5147-25.8607-48.4417-70.9035-84.9963-91.4326QC'd by SIGMA
Inhibitor2.590198.49686Complete curve; high efficacy-5.58674.0950.9994-101.9353-3.4393-1.10 0 0 0 0 0 0 0 0 0 0-102.3447-3.0022-2.6536-4.2124-2.3934-2.0327-2.9719-4.1726-25.8834-97.2501-101.4914-102.3447QC'd by NCGCChem
Inhibitor2.5901105.413785Complete curve; high efficacy-5.58670.80.9976-100.41375-1.10 0 0 0 0 0 0 0 0 0 0-90.95457.53544.46353.58863.2188-2.4359-10.3973-17.5405-39.749-63.8592-82.3674-90.9545QC'd by Tocris
Inhibitor12.98185.533582Complete curve; high efficacy-4.88674.95490.9967-87.5434-2.0099-1.10 0 0 0 0 0 0 0 0 0 0-85.325-1.8297-3.5602-3.91-1.0422-1.2527-1.4075-3.9675-0.4249-0.4411-70.6158-85.325QC'd by Sytravon
Inhibitor4.10593.343644Partial curve; partial efficacy-5.38670.70.9979-89.84363.5-2.20 0 0 0 0 0 0 0 0 0 0-77.65374.60332.57411.55570.6086-2.727-5.8785-14.7051-32.247-48.4602-62.0742-77.6537QC'd by APAC
Inhibitor9.189981.712442Partial curve; partial efficacy-5.03671.10.9987-84.3066-2.5942-2.20 0 0 0 0 0 0 0 0 0 0-72.9596-2.0933-3.4233-3.1998-2.8829-2.6472-1.7452-7.9092-14.2316-31.7647-56.8608-72.9596QC'd by Glixx
Inhibitor18.336272.984941Partial curve; partial efficacy-4.73672.04790.956-75.9849-3-2.20 0 0 0 0 0 0 0 0 0 0-70.3563-1.7343-12.6104-4.1714.03140.7429-2.4048-1.3619-5.566-12.2596-31.5981-70.3563QC'd by Princeton
Inhibitor18.336273.450741Partial curve; partial efficacy-4.73671.53860.9946-82.1193-8.6686-2.20 0 0 0 0 0 0 0 0 0 0-72.0345-7.7697-8.6785-9.0916-9.479-8.3494-7.2238-9.8284-10.1223-21.6905-41.8484-72.0345QC'd by Microsource
Inhibitor23.083988.658741Partial curve; high efficacy-4.63672.40640.9832-92.503-3.8444-2.10 0 0 0 0 0 0 0 0 0 0-90.6892-3.5026-2.9812-3.2189-4.6998-1.9536-5.3552-5.0547-4.555-8.1241-29.8904-90.6892QC'd by NCGCChem
Inhibitor2.906155.229123Complete curve; partial efficacy-5.53670.70.9915-52.22913-1.20 0 0 0 0 0 0 0 0 0 0-45.24942.53842.22822.66160.2019-1.9921-2.393-10.3912-22.8963-27.6273-41.5174-45.2494QC'd by MedChem Express
Inhibitor16.342181.36321Partial curve; partial efficacy-4.78671.28760.9793-77.8633.5-2.20 0 0 0 0 0 0 0 0 0 0-64.88584.62066.61036.34755.43191.9795-3.94211.1208-2.7854-12.2731-33.9047-64.8858QC'd by Microsource
Inhibitor18.336258.528921Partial curve; partial efficacy-4.73671.22210.9689-56.02892.5-2.20 0 0 0 0 0 0 0 0 0 0-46.69084.23963.60586.59553.80761.7487-1.2158-0.5062-1.333-10.3615-20.7839-46.6908QC'd by Microsource
Inhibitor18.336263.657421Partial curve; partial efficacy-4.73671.10.931-61.15742.5-2.20 0 0 0 0 0 0 0 0 0 0-50.96456.82263.13523.21093.8242.1658-3.03871.5869-9.9978-10.7579-20.2792-50.9645QC'd by MedChem Express
Inhibitor16.017653.680221Partial curve; partial efficacy-4.79541.10.9332-59.7413-6.061-2.20 0 0 0 0 0 0 0 0 0 0-47.4137-9.9147-8.0265-4.9002-7.74-1.7175-9.128-10.8321-13.0781-14.6739-24.7757-47.4137QC'd by Analyticon
Inhibitor11.273938.61321Partial curve; partial efficacy-4.94791.3310.9367-43.2673-4.6543-2.20 0 0 0 0 0 0 0 0 0 0-36.0561-3.0892-0.9619-5.6766-4.829-2.5548-6.7305-9.0092-6.7736-9.551-16.7432-36.0561QC'd by Analyticon
Inhibitor14.564967.495921Partial curve; partial efficacy-4.83671.10.983-68.9959-1.5-2.20 0 0 0 0 0 0 0 0 0 0-54.16350.8818-0.2331-1.50670.5982-1.1965-4.6761-8.0636-7.7637-15.5972-40.2452-54.1635QC'd by Glixx
Inhibitor16.342164.033421Partial curve; partial efficacy-4.78671.24750.987-60.03344-2.20 0 0 0 0 0 0 0 0 0 0-50.02786.60443.85072.66763.5393.9191.76213.45141.0614-12.3878-25.4689-50.0278QC'd by SIGMA
Inhibitor18.336270.455621Partial curve; partial efficacy-4.73671.62590.9803-68.95561.5-2.20 0 0 0 0 0 0 0 0 0 0-60.48735.82951.2932.17034.24110.8209-1.49341.094-2.4894-11.3309-27.749-60.4873QC'd by SIGMA
Inhibitor18.336252.926821Partial curve; partial efficacy-4.73671.41630.9896-55.8043-2.8775-2.20 0 0 0 0 0 0 0 0 0 0-46.5035-5.734-1.7587-1.7696-3.3881-1.8874-1.1479-3.8743-3.938-12.2677-26.0707-46.5035QC'd by Scientific Exchange
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Histone deacetylase 6
External ID: CHEMBL4808150
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL1865
ChEMBL Target Name: Histone deacetylase 6
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: Fraunhofer Institute HDAC6 screening
Standard TypeStandard RelationStandard ValueStandard Text ValueStandard UnitsData Validity Comment
Inhibition=-7.39%
Inhibition=-3.08%
Inhibition=97.8%
Inhibition=-9.09%
Inhibition=47.05%
Inhibition=-5.94%
Inhibition=-0.48%
Inhibition=-2.98%
Inhibition=1.42%
Inhibition=12.25%
Inhibition=-2.13%
Inhibition=-4.43%
Inhibition=4.53%
Inhibition=-5.82%
Inhibition=10.36%
Inhibition=-1.3%
Inhibition=12.9%
Inhibition=-3.37%
Inhibition=3.17%
Inhibition=-0.97%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Enzyme; 2 uL; 1,536-well solid-bottom, black plate (Greiner Bio One).
2; Compounds; 20 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 2 uL; Ac-DE-[Lys(5-TAMRA)]-EE-[Abu-psi(COO)Ala]-S-[Lys(ECLIPSE-7)]-amide.
5; Detection; Fluorescence; time 0, ViewLux microplate reader (PerkinElmer) 525 nm excitation, 598/25 nm emission
6; Incubation; 15 min; room temperature
7; Detection; Fluorescence; time 15; ViewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Two microliter of NS3-4A HCV enzyme solution (5 nM final concentration) in assay buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, with 0.01% Tween 20) were dispensed into a 1,536-well solid-bottom black plate (Greiner Bio One) using the Kalypsys Pintool Station.
2. Twenty nanoliter of compounds, positive control Aprotinin (50 uM final concentration), or neutral control DMSO were transferred to the assay plates. Compounds in counter-screen assays were tested at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
3. The assay plates were incubated in the dark for 15 min.
4. After incubation, 2 uL of 0.625 uM substrate (Ac-DE-[Lys(5-TAMRA)]-EE-[Abu-psi(COO)Ala]-S-[Lys(ECLIPSE-7)]-amide) in assay buffer (for NS3-4A assay) was added using the Kalypsys Pintool Station.
5-7. Plates were immediately read at time 0 then covered with stainless steel gasket lids and incubated for 15 min at room temperature in the dark. Fluorescence intensity in the assay plates were again read after incubation using the ViewLux imager equipped with Tamara fluorescence optics. The change in fluorescence intensity over the 15-min reaction period was normalized against DMSO and inhibitor controls as described below.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008333407 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00748 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.115 uMActivity at 0.206 uMActivity at 0.344 uMActivity at 0.619 uMActivity at 1.033 uMActivity at 1.912 uMActivity at 3.719 uMActivity at 5.737 uMActivity at 11.16 uMActivity at 17.21 uMActivity at 33.48 uMActivity at 50.94 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor0.25992.105390Complete curve; high efficacy-6.58673.990.9964-92.10530-1.10 0 0 0 0 0 0 0 0 1 1000000-26.9057-94.1772-91.9507-86.4857-67.71240QC'd by GVK
Inhibitor0.205796.846490Complete curve; high efficacy-6.68670.50.9869-93.84643-1.10 0 0 0 0 0 0 0 0 0 0-88.36761.1189-13.0457-11.9936-16.2335-34.002-49.7919-58.5074-65.2049-76.2052-87.4254-88.3676QC'd by Cayman
Inhibitor0.81998.080488Complete curve; high efficacy-6.08674.95490.9998-98.08040-1.10 0 0 0 0 0 0 0 0 0 0-99.071100000-1.3807-18.4263-95.594-97.8277-98.7603-99.0711QC'd by SigmaAldrich
Inhibitor1.833690.267186Complete curve; high efficacy-5.736710.9788-90.7671-0.5-1.10 0 0 0 0 0 0 0 0 0 0-90.0467-11.97791.8615-1.11490.31450.4826-1.9658-28.8777-45.643-65.5697-80.455-90.0467QC'd by Sytravon
Inhibitor1.634297.729886Complete curve; high efficacy-5.78671.1110.9949-91.72986-1.10 0 0 0 0 0 0 0 0 0 0-91.54674.74716.6915.74934.61264.6496-4.2191-15.4016-52.1541-67.1067-83.4886-91.5467QC'd by Sytravon
Inhibitor1.634280.443285Complete curve; high efficacy-5.78671.41630.9844-82.9432-2.5-1.10 0 0 0 0 0 0 0 0 0 0-86.94260.0017-2.7057-0.96350.2371-10.9118-7.4073-13.1382-51.7572-66.8444-76.6984-86.9426QC'd by Sytravon
Inhibitor11.5693142.296983Complete curve; high efficacy-4.93674.95490.9843-146.2969-4-1.10 0 0 0 0 0 0 0 0 0 0-145.1358-11.1377-4.9584-14.1999-14.9851-11.52250000-127.65-145.1358QC'd by BOC Sciences
Inhibitor2.982882.380383Complete curve; high efficacy-5.52541.1110.9956-67.380315-1.10 0 0 0 0 0 0 0 0 0 0-66.408515.731216.408516.690113.75649.84876.8460.9994-27.4034-46.3695-59.0006-66.4085QC'd by ChemRoutes
Inhibitor5.167882.670583Complete curve; high efficacy-5.28671.69240.9917-84.1705-1.5-1.10 0 0 0 0 0 0 0 0 0 0-84.00242.33990.0403-2.9808-0.1304-2.852-3.4511-8.3788-9.4642-47.6561-71.3126-84.0024QC'd by ChemRoutes
Inhibitor0.579874.517767Complete curve; partial efficacy-6.23671.78850.9905-84.7108-10.1932-1.20 0 0 0 0 0 0 0 0 0 0-85.7922-6.411-13.187-13.2655-8.1855-13.3519-15.8017-54.0083-71.981-81.2068-87.6924-85.7922QC'd by Pharmaron
Inhibitor4.10572.3264Complete curve; partial efficacy-5.38671.50950.9933-89.4126-17.0927-1.20 0 0 0 0 0 0 0 0 0 0-90.3158-20.231-13.4106-18.193-17.5607-16.7098-16.5249-21.8958-32.2241-62.637-77.852-90.3158QC'd by Sytravon
Inhibitor10.311271.125562Complete curve; partial efficacy-4.98672.40640.9806-86.3626-15.2371-1.20 0 0 0 0 0 0 0 0 0 0-85.1702-13.7671-12.9532-14.248-25.2859-13.461-15.2839-12.6976-15.193-27.0044-68.8421-85.1702QC'd by Analyticon
Inhibitor9.189967.032862Complete curve; partial efficacy-5.03671.82650.9939-76.8664-9.8336-1.20 0 0 0 0 0 0 0 0 0 0-70.7322-10.7907-8.6988-8.6114-9.0149-11.4364-9.2773-12.7817-14.9845-27.5022-61.3355-70.7322QC'd by Chemdiv
Inhibitor8.1905106.357343Partial curve; high efficacy-5.08670.50.9661-114.4951-8.1378-2.10 0 0 0 0 0 0 0 0 0 0-86.7387-3.4482-13.2288-17.8624-15.8022-16.7275-16.6046-30.643-44.1175-47.0452-75.7003-86.7387QC'd by BIOMOL
Inhibitor11.5693128.704843Partial curve; high efficacy-4.93673.29750.9933-121.20487.5-2.10 0 0 0 0 0 0 0 0 0 0-121.6916-2.99137.44749.60127.73788.80399.956610.49748.9646-2.3207-89.0932-121.6916QC'd by NCGCChem
Inhibitor12.98167.215642Partial curve; partial efficacy-4.88671.10.9972-84.7948-17.5792-2.20 0 0 0 0 0 0 0 0 0 0-72.5718-16.8006-15.8993-18.304-17.8466-17.1874-19.286-19.9586-25.6491-34.807-56.3917-72.5718QC'd by Analyticon
Inhibitor16.3421132.313242Partial curve; high efficacy-4.78671.28760.9936-133.8132-1.5-2.10 0 0 0 0 0 0 0 0 0 0-111.511-1.0773-3.27710.19161.699-3.4092-5.8988-5.8666-5.6959-30.4121-64.6714-111.511QC'd by Life Chemicals
Inhibitor20.573598.567741Partial curve; high efficacy-4.68673.06540.9967-98.56770-2.10 0 0 0 0 0 0 0 0 0 0-96.6351.366200000000-36.802-96.635QC'd by APExBIO
Inhibitor23.0839122.554341Partial curve; high efficacy-4.63674.0950.8771-108.817213.7371-2.10 0 0 0 0 0 0 0 0 0 0-101.695-5.92085.54383.16447.27436.362713.609223.729537.428332.861-14.4157-101.695QC'd by NCGCChem
Inhibitor0.650655.936625Complete curve; partial efficacy-6.18672.72020.9428-55.43660.5-1.20 0 0 0 0 0 0 0 0 0 0-56.768000000-22.2431-60.7149-64.5173-39.0284-56.768QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-full-length
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL NSP2 full length enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008233323 uMActivity at 0.00124 uMActivity at 0.00246 uMActivity at 0.00377 uMActivity at 0.00739 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.039 uMActivity at 0.069 uMActivity at 0.117 uMActivity at 0.206 uMActivity at 0.351 uMActivity at 0.618 uMActivity at 1.053 uMActivity at 1.927 uMActivity at 3.720 uMActivity at 5.782 uMActivity at 11.16 uMActivity at 17.34 uMActivity at 33.48 uMActivity at 50.65 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor1.0311106.093288Complete curve; high efficacy-5.986710.99-101.59324.5-1.10 0 0 0 0 0 0 0 0 0 0-98.4439.69810.004410.7127-6.9536-2.2974-11.3519-36.1756-62.6061-84.2015-97.0708-98.443QC'd by SigmaAldrich
Inhibitor0.919111.417488Complete curve; high efficacy-6.03671.10.9849-97.917413.5-1.10 0 0 0 0 0 0 0 0 0 0-96.36467.404918.91937.176321.7697-0.27442.4876-34.3663-61.0045-84.521-92.9929-96.3646QC'd by Selleck
Inhibitor1.4565108.77387Complete curve; high efficacy-5.83670.90.9912-101.2737.5-1.10 0 0 0 0 0 0 0 0 0 0-98.132810.07855.0453-2.210212.6454-0.7438-8.1305-26.4248-53.3465-74.5675-90.2675-98.1328QC'd by Selleck
Inhibitor1.2981107.823587Complete curve; high efficacy-5.886710.9927-101.32356.5-1.10 0 0 0 0 0 0 0 0 0 0-97.05321.48227.484311.22584.259-2.139-4.1769-31.5222-52.5312-85.691-92.9687-97.0532QC'd by Tocris
Inhibitor1.156992.80487Complete curve; high efficacy-5.93671.210.976-96.804-4-1.10 0 0 0 0 0 0 0 0 0 0-96.03577.5254-14.9467-7.974-2.01-12.1318-6.5988-36.504-61.4538-83.187-95.332-96.0357QC'd by SIGMA
Inhibitor1.456595.066587Complete curve; high efficacy-5.836710.9926-99.0665-4-1.10 0 0 1 0 0 0 0 0 0 0-95.99472.226-3.6974-10.351930.2584-11.8423-14.0904-31.1299-59.4844-78.33-91.9831-95.9947QC'd by NCGCChem
Inhibitor1.8336110.365186Complete curve; high efficacy-5.73671.24750.9945-99.365111-1.10 0 0 0 0 0 0 0 0 0 0-94.995815.797610.24626.95079.791910.4877.1488-16.8798-40.2744-77.7593-95.7275-94.9958QC'd by Microsource
Inhibitor2.0574107.49186Complete curve; high efficacy-5.68671.22210.9783-93.49114-1.10 0 0 0 0 0 0 0 0 0 0-92.234113.63262.353916.684313.807818.062618.6688-16.6338-34.2006-66.3978-87.0605-92.2341QC'd by Sytravon
Inhibitor2.0574110.033386Complete curve; high efficacy-5.68670.90.9865-101.53338.5-1.10 0 0 0 0 0 0 0 0 0 0-94.53752.57514.84352.581314.72980.6931-8.9626-15.325-43.8815-68.5449-89.3213-94.5375QC'd by Sytravon
Inhibitor1.4193104.591986Complete curve; high efficacy-5.84791.22210.9804-95.59199-1.10 0 0 0 0 0 0 0 0 0 0-91.56313.338212.1183.45719.685216.62987.975-15.319-22.3855-65.6932-86.2038-91.5631QC'd by Microsource
Inhibitor2.906193.574185Complete curve; high efficacy-5.53671.10.9812-95.0741-1.5-1.10 0 0 0 0 0 0 0 0 0 0-87.5452-10.254-2.4392-6.9481-0.21635.7988-1.9135-16.6748-36.4819-65.1695-80.976-87.5452QC'd by Sytravon
Inhibitor3.260799.032985Complete curve; high efficacy-5.48671.34430.9632-93.53295.5-1.10 0 0 0 0 0 0 0 0 0 0-91.6989-3.2822-3.856916.56124.99049.207314.3935-14.7708-21.951-60.88-83.1689-91.6989QC'd by Sytravon
Inhibitor4.10587.564284Complete curve; high efficacy-5.38671.34430.9761-91.5642-4-1.10 0 0 0 0 0 0 0 0 0 0-86.7085-6.111-5.8563-10.9621-8.20018.6265-8.333-8.9422-26.9277-56.1051-82.3696-86.7085QC'd by Sytravon
Inhibitor4.10594.757984Complete curve; high efficacy-5.38672.53340.9206-89.75795-1.10 0 0 0 0 0 0 0 0 0 0-94.487-2.0682-6.881818.97199.079426.6747-3.0833-13.5252-0.671-59.3912-82.4679-94.487QC'd by Sytravon
Inhibitor5.1678111.309384Complete curve; high efficacy-5.28671.1110.972-99.809311.5-1.10 0 0 0 0 0 0 0 0 0 0-90.123318.46670.454721.0592.25616.804310.3614-3.5838-12.6269-47.0769-77.3938-90.1233QC'd by Sytravon
Inhibitor4.7274110.237784Complete curve; high efficacy-5.32540.90.9989-105.23775-1.10 0 0 0 0 0 0 0 0 0 0-95.3244.46492.41734.84984.69613.5345-3.5636-16.4321-36.8529-65.4142-85.8945-95.324QC'd by ChemRoutes
Inhibitor6.6764102.715483Complete curve; high efficacy-5.175510.9925-85.715417-1.10 0 0 0 0 0 0 0 0 0 0-78.274524.400614.971411.383313.800814.663512.97462.3962-20.6265-48.4262-68.5588-78.2745QC'd by SigmaAldrich
Inhibitor6.505996.411583Complete curve; high efficacy-5.18671.98870.985-81.911514.5-1.10 0 0 0 0 0 0 0 0 0 0-82.35358.798114.34957.773819.733320.147916.82811.749112.1698-29.6807-65.7541-82.3535QC'd by Microsource
Inhibitor9.189994.261583Complete curve; high efficacy-5.03674.95490.984-98.2615-4-1.10 0 1 0 0 0 0 0 0 0 0-96.33483.9892-13.509951.244-3.2532-4.06541.2359-5.945-8.4138-9.4606-95.1238-96.3348QC'd by SIGMA
Inhibitor7.299894.557283Complete curve; high efficacy-5.13671.66040.9244-98.5572-4-1.10 0 0 0 0 0 0 0 0 0 0-91.766513.2607-14.95846.5402-15.1959-12.7095-5.0389-9.5867-19.5062-34.0351-85.2014-91.7665QC'd by Cayman
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1218236
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f18-cell-based
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1a; Cell Transfection; Lipofectamine 2000.
1b; Cell; 4 uL; Aurora 1536-well, white, tissue culture plate.
2; Incubation; 4 hr; 37C, 5% CO2, 95% humidity.
3; Compound; 20 nL; Echo 650 Liquid Handler.
4; Incubation; overnight; 37C, 55 CO2, 95% humidity.
5; Reagent; 4 uL; Nano-Glo Luciferase assay system.
6; Centrifugation; 2 sec.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to sequence numbers above).
1a. For the 1,536-well assay, cells were transfected in T75 flasks using a reverse transfection procedure, where 9 mL of complexes containing 45 uL Lipofectamine 2000 (ThermoFisher Scientific), 20 ug nsP2 plasmid, and 0.2 ug Nluc reporter plasmid, were combined with 10 mL of HEK293T cell suspension (1x10^6 cells/mL, 10 million cells total). Complexes containing Transfection Carrier DNA (Promega) and Nluc reporter plasmid (also at 1:100 ratio) were used as a high-signal control. After 24h, cells were harvested by trypsinization and resuspended at a density of 1x10^6 cells/ml.
1b. Cells were dispensed (4 uL cell/well) into 1,536-well white plates (Aurora, cyclic olefin polymer, cat# EWB041000A) using a Multidrop Combi.
2-4. After 4 hours, compounds (20 nL) were subsequently pinned using an Echo 650 Series Liquid Handlers and incubated overnight at 37C.
5. Nano-Glo (Promega) reagent was added (4 uL /well) according to the manufacturer's recommendations.
6-7. The Plates were centrifuged and analyzed for luminescence intensity using a ViewLux reader.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008286089 uMActivity at 0.00124 uMActivity at 0.00248 uMActivity at 0.00373 uMActivity at 0.00744 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.040 uMActivity at 0.069 uMActivity at 0.111 uMActivity at 0.206 uMActivity at 0.353 uMActivity at 0.624 uMActivity at 1.115 uMActivity at 1.930 uMActivity at 3.480 uMActivity at 5.807 uMActivity at 11.67 uMActivity at 17.60 uMActivity at 33.48 uMActivity at 51.06 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor1.412597.022587Complete curve; high efficacy-5.850.90.957-104.5706-7.5482-1.10 0 0 0 0 0 0 0 0 0 0-97.2822-11.2901-18.8772-11.6693-43.4765-44.248-44.8652-79.0266-84.1272-97.3439-97.9126-97.2822QC'd by GVK
Inhibitor1.4565126.346487Complete curve; high efficacy-5.83671.69240.9931-110.846415.5-1.11 0 0 0 0 0 0 0 0 0 0-107.409337.871713.682213.064213.776920.336416.8573-14.9483-55.8355-105.909-107.0903-107.4093QC'd by Chemdiv
Inhibitor0.4606100.414987Complete curve; high efficacy-6.33674.95490.928-79.296321.1186-1.10 0 0 0 0 0 0 0 0 0 0-80.69525.98363.899320.805713.096232.323152.0621-68.7904-68.3183-79.5773-81.684-80.6952QC'd by Chemdiv
Inhibitor2.0574127.04387Complete curve; high efficacy-5.68671.46410.9422-115.04312-1.10 0 0 0 0 0 0 0 0 0 0-108.296627.274827.23495.92651.1464-4.6804-0.5882-17.3408-29.4928-107.7134-107.9427-108.2966QC'd by NCGCChem
Inhibitor2.5901129.453786Complete curve; high efficacy-5.58671.82650.9531-115.953713.5-1.10 0 0 0 0 0 0 0 0 0 0-106.89125.29617.7047-2.168223.67114.5545-10.467319.514-32.1645-97.9389-107.1103-106.891QC'd by Sytravon
Inhibitor2.590197.869686Complete curve; high efficacy-5.58674.50450.9733-101.8696-4-1.10 0 0 0 0 0 0 0 0 0 0-102.3291-9.4766-13.236-4.3824-14.7087-2.633912.43521.8642-20.9241-97.3951-102.8986-102.3291QC'd by Chemdiv
Inhibitor2.0574116.348186Complete curve; high efficacy-5.68672.25260.9818-104.848111.5-1.10 0 0 0 0 0 0 0 0 0 0-99.988917.87645.414518.601721.38231.31256.6781-1.5616-36.6071-101.7374-101.5594-99.9889QC'd by NCGCChem
Inhibitor4.6058118.776985Complete curve; high efficacy-5.33673.990.9688-109.27699.5-1.10 0 0 0 0 0 0 0 0 0 0-107.319627.49919.9838-0.73770.5034-4.102211.125217.550211.1202-74.9358-107.3595-107.3196QC'd by Sytravon
Inhibitor5.6234109.163984Complete curve; high efficacy-5.251.88510.9652-105.16394-1.10 0 0 0 0 0 0 0 0 0 0-96.78411.62524.71273.4254-4.5143-4.9331-20.5877-16.0337-50.9533-98.0537-98.468-96.784QC'd by DC Chemicals
Inhibitor7.2998107.495784Complete curve; high efficacy-5.13671.22210.9783-111.4957-4-1.10 0 0 0 0 0 0 0 0 0 0-103.2367-13.2538-0.02672.0065-5.81943.6661-9.6857-15.95-22.7304-46.7644-84.8842-103.2367QC'd by NCGCChem
Inhibitor11.569397.536882Complete curve; high efficacy-4.93674.95490.9485-101.0368-3.5-1.10 0 0 0 0 0 0 0 0 0 0-99.6418-12.43523.0387-14.6153-12.22614.35122.43818.8048-13.72541.3125-89.3911-99.6418QC'd by Chembridge
Inhibitor11.569398.82882Complete curve; high efficacy-4.93674.50450.9121-102.828-4-1.10 0 0 0 0 0 0 0 0 0 0-102.6227-1.8731-15.5763-26.5166-12.5464-17.5339-1.8642-10.07279.9126-6.6647-86.3836-102.6227QC'd by Vitas
Inhibitor23.083979.475841Partial curve; partial efficacy-4.63674.0950.8235-82.9758-3.5-2.20 0 0 0 0 0 0 0 0 0 0-77.0049-11.7145-10.8602-14.62426.090818.6951-3.1322-12.0125-9.70796.7448-19.7584-77.0049QC'd by NCGCChem
Inhibitor20.573599.804841Partial curve; high efficacy-4.68671.71370.8734-98.30481.5-2.10 0 0 0 0 0 0 0 0 0 0-86.23230.8676-9.5389-7.5191.041115.211411.478716.8843-15.6741-12.7422-33.4839-86.2323QC'd by NCGCChem
Inhibitor20.573583.186341Partial curve; partial efficacy-4.68672.72020.8668-73.68639.5-2.20 0 0 0 0 0 0 0 0 0 0-73.338822.12982.3847-10.384210.49990.102319.660520.92419.88146.9673-17.4182-73.3388QC'd by NCGCChem
Inhibitor18.3362121.834541Partial curve; high efficacy-4.73672.78680.9485-108.334513.5-2.11 0 0 0 0 0 0 0 0 0 0-101.2702-23.8516-2.073330.62758.119614.1175.098717.920920.43917.8615-40.4645-101.2702QC'd by Chembridge
Inhibitor20.573584.41341Partial curve; partial efficacy-4.68672.33320.892-78.4136-2.20 0 0 0 0 0 0 0 0 0 0-72.8494-2.82072.460317.213514.93561.846412.4664-6.695915.6163-7.5679-24.6257-72.8494QC'd by NCGCChem
Inhibitor20.573592.825941Partial curve; high efficacy-4.68674.0950.9171-78.325914.5-2.10 0 0 0 0 0 0 0 0 0 0-73.226310.5264-3.15115.104918.850515.991227.25478.379713.951423.9589-13.1452-73.2263QC'd by NCGCChem
Inhibitor20.573583.187141Partial curve; high efficacy-4.68673.1320.8423-62.127821.0593-2.10 0 0 0 0 0 0 0 0 0 0-64.6929-2.536422.293214.267618.280420.7337.992716.454438.665223.812-8.8563-64.6929QC'd by NCGCChem
Inhibitor0.579833.910523Complete curve; partial efficacy-6.23674.44950.9281-32.91051-1.20 0 0 0 0 0 0 0 0 0 0-32.7721-6.1106-3.99926.126-3.02061.918710.2023-19.0021-31.9399-32.7413-33.1189-32.7721QC'd by Cayman
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1218235
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f5_f16-endo
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM endogenous NS2/3 peptide substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of endogenous NS2/3 peptide substrate (peptide 3: TMR-DELRLDRAGC/APSYR-K-QSY7; 2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008338173 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00749 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.114 uMActivity at 0.206 uMActivity at 0.342 uMActivity at 0.619 uMActivity at 1.026 uMActivity at 1.916 uMActivity at 3.719 uMActivity at 5.749 uMActivity at 11.16 uMActivity at 17.25 uMActivity at 33.47 uMActivity at 51.01 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor0.81987.038587Complete curve; high efficacy-6.08671.34430.9961-84.53852.5-1.10 0 0 0 0 0 0 0 0 0 0-87.51391.114002.97934.2662-7.9466-33.2435-61.766-76.6432-81.3334-87.5139QC'd by SIGMA
Inhibitor1.634289.661386Complete curve; high efficacy-5.78670.80.9918-94.197-4.5357-1.10 0 0 0 0 0 0 0 0 0 0-90.227-2.5297-3.4679-9.635-7.1695-14.792-15.9048-29.4095-56.4408-69.3217-79.2648-90.227QC'd by APAC
Inhibitor1.833694.496186Complete curve; high efficacy-5.73671.86170.9989-94.9961-0.5-1.10 0 0 0 0 0 0 0 0 0 0-95.3776-1.3502-0.2066-2.42582.7774-1.6197-2.0908-11.2497-47.9814-82.942-94.0736-95.3776QC'd by Selleck
Inhibitor1.833698.758986Complete curve; high efficacy-5.73671.80790.9926-96.25892.5-1.10 0 0 0 0 0 0 0 0 0 0-96.17612.1633-3.0162-1.73913.83766.88923.9784-5.961-50.1564-79.4444-97.2312-96.1761QC'd by Chembridge
Inhibitor1.8336117.551786Complete curve; high efficacy-5.73671.1110.9917-104.051713.5-1.10 0 0 0 0 0 0 0 0 0 0-99.203816.02712.528420.739610.99283.40560.7171-11.6101-40.2962-81.8609-95.3712-99.2038QC'd by NCGCChem
Inhibitor4.105102.203385Complete curve; high efficacy-5.38672.78680.9963-102.20330-1.10 0 0 0 0 0 0 0 0 0 0-100.6552000.44662.61961.3014-7.0848-0.1399-9.5349-70.1791-102.6138-100.6552QC'd by Microsource
Inhibitor3.177496.712985Complete curve; high efficacy-5.49791.62660.9968-95.71291-1.10 0 0 0 0 0 0 0 0 0 0-88.623100.724301.163100-0.2194-6.346-40.8346-79.8345-88.6231QC'd by Analyticon
Inhibitor6.5059128.088785Complete curve; high efficacy-5.18671.53860.9928-132.0887-4-1.10 0 0 0 0 0 0 0 0 0 0-129.49870.1476-4.8849-6.6137-8.5236-3.9326-10.9532-8.9047-15.3414-65.574-105.6081-129.4987QC'd by Axon Medchem
Inhibitor2.906193.696885Complete curve; high efficacy-5.53671.82650.9956-91.69682-1.10 0 0 0 0 0 0 0 0 0 0-89.373104.594604.2711000.8493-27.8387-73.8967-86.3827-89.3731QC'd by Cayman
Inhibitor3.2607111.298885Complete curve; high efficacy-5.48672.04790.9948-99.298812-1.10 0 0 0 0 0 0 0 0 0 0-96.590715.559213.836617.029410.599911.54637.65512.3867-12.0459-71.5767-97.3518-96.5907QC'd by NCGCChem
Inhibitor3.658592.976984Complete curve; high efficacy-5.43671.69240.9965-92.47690.5-1.10 0 0 0 0 0 0 0 0 0 0-90.6636000003.988-8.3142-20.7831-59.875-87.9355-90.6636QC'd by SigmaAldrich
Inhibitor5.798495.974484Complete curve; high efficacy-5.23672.33320.9922-96.9744-1-1.10 0 0 0 0 0 0 0 0 0 0-93.0365-0.68670.424801.8559-0.4094-1.8277-5.021-11.0122-41.926-95.6355-93.0365QC'd by SIGMA
Inhibitor4.6058102.119684Complete curve; high efficacy-5.33673.92950.9779-94.61967.5-1.10 0 0 0 0 0 0 0 0 0 0-85.5338-0.64041.64322.67266.208310.280816.117412.58977.6496-60.847-103.7496-85.5338QC'd by Sytravon
Inhibitor4.6058107.458184Complete curve; high efficacy-5.33671.47810.992-98.95818.5-1.10 0 0 0 0 0 0 0 0 0 0-93.18098.83129.08824.19858.57956.83810.28788.55-19.9304-49.1765-88.9783-93.1809QC'd by Sytravon
Inhibitor5.798498.695684Complete curve; high efficacy-5.23671.1110.9913-96.69562-1.10 0 0 0 0 0 0 0 0 0 0-90.03320.44413.12146.06443.2241-5.00040-5.7269-22.3838-41.1315-74.3311-90.0332QC'd by Selleck
Inhibitor6.5059101.664984Complete curve; high efficacy-5.18671.28760.9986-106.4121-4.7472-1.10 0 0 0 0 0 0 0 0 0 0-99.6368-3.7525-4.5439-5.9657-1.8727-5.3345-7.423-10.2197-20.0785-51.0609-82.5103-99.6368QC'd by Analyticon
Inhibitor5.035990.647784Complete curve; high efficacy-5.29793.62720.9923-92.6477-2-1.10 0 0 0 0 0 0 0 0 0 0-92.46282.39754.229-3.4667-5.4432-3.7131-3.5860.2734-4.8695-11.6501-80.2351-92.4628QC'd by Prestwick
Inhibitor5.7984107.791584Complete curve; high efficacy-5.23671.92820.99-98.79159-1.10 0 0 0 0 0 0 0 0 0 0-95.174810.4673-0.8557.541910.130413.460114.96026.5091-1.1759-44.2917-87.5379-95.1748QC'd by Chemdiv
Inhibitor4.7166102.054884Complete curve; high efficacy-5.32641.86170.9952-99.55482.5-1.10 0 0 0 0 0 0 0 0 0 0-97.60283.9695-2.5222-0.88844.87277.42362.1813-0.4619-13.1259-55.3921-92.8344-97.6028QC'd by Vitas
Inhibitor5.1678114.21784Complete curve; high efficacy-5.28671.55790.995-99.71714.5-1.10 0 0 0 0 0 0 0 0 0 0-94.569816.45520.153114.577812.385915.02249.87235.3386-3.7884-44.983-85.8105-94.5698QC'd by Chemdiv
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1218234
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f19-rhfurin
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Enzyme; 2 uL; 1,536-well solid-bottom, black plate (Greiner Bio One).
2; Compounds; 20 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 2 uL; pERTKR-AMC.
5; Detection; Fluorescence; time 0, Viewlux microplate reader (PerkinElmer) 355 nm excitation, 460 nm emission
6; Incubation; 15 min; room temperature
7; Detection; Fluorescence; time 15; ViewLux microplate reader (PerkinElmer), 355 nm excitation, 460 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Two micro-liter of furin enzyme solution (40 nM final concentration) in assay buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, with 0.01% Tween 20) were dispensed into a 1,536-well solid-bottom black plate (Greiner Bio One) using the Kalypsys Pintool Station.
2. Twenty nano-liter of compounds, positive control Aprotinin (50 uM final concentration), or neutral control DMSO were transferred to the assay plates. Compounds in counterscreen assays were tested at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
3. The assay plates were incubated in the dark for 15 min.
4. After incubation, 2 uL of 0.625 uM pERTKR-AMC substrate in assay buffer for the Furin assay was added using the Kalypsys Pintool Station.
5-7. Plates were immediately read at time 0 then covered with stainless steel gasket lids and incubated for 15 min at room temperature in the dark. Fluorescence intensity in the assay plates were again read after incubation using the ViewLux imager equipped with AMC fluorescence optics. The change in fluorescence intensity over the 15-min reaction period was normalized against DMSO and inhibitor controls as described below.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008234935 uMActivity at 0.00124 uMActivity at 0.00246 uMActivity at 0.00377 uMActivity at 0.00739 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.039 uMActivity at 0.069 uMActivity at 0.117 uMActivity at 0.206 uMActivity at 0.352 uMActivity at 0.618 uMActivity at 1.055 uMActivity at 1.924 uMActivity at 3.720 uMActivity at 5.772 uMActivity at 11.16 uMActivity at 17.32 uMActivity at 33.48 uMActivity at 50.62 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor2.0574123.268587Complete curve; high efficacy-5.68672.40640.9964-118.26855-1.10 0 0 0 0 0 0 0 0 0 0-115.09082.8885.40046.58594.04132.80793.37932.2835-43.9445-114.475-115.9495-115.0908QC'd by SIGMA
Inhibitor2.0574120.450687Complete curve; high efficacy-5.68672.33320.9968-118.45062-1.10 0 0 0 0 0 0 0 0 0 0-116.81524.9144-0.21651.34233.41651.011-2.1306-5.6378-45.6943-113.1005-116.7151-116.8152QC'd by Bio Vision
Inhibitor4.105101.938684Complete curve; high efficacy-5.38672.84730.9578-98.43863.5-1.10 0 0 0 0 0 0 0 0 0 0-116.35774.70634.88514.14443.42941.8409-0.45260.3312-2.0485-70.9205-76.0559-116.3577QC'd by Adooq
Inhibitor7.299892.071783Complete curve; high efficacy-5.13671.88510.982-90.07172-1.10 0 0 0 0 0 0 0 0 0 0-80.90751.9866-0.00341.8592.45192.61364.709-0.0577-7.01-25.1697-83.0089-80.9075QC'd by APAC
Inhibitor9.1899126.48883Complete curve; high efficacy-5.03674.95490.9935-123.4883-1.10 0 0 0 0 0 0 0 0 0 0-120.35874.684812.69580.55870.49710.5341.43890.9107-0.7262-3.4411-118.5135-120.3587QC'd by MedChem Express
Inhibitor7.9813140.948544Partial curve; high efficacy-5.09791.1110.9968-139.44851.5-2.10 0 0 0 0 0 0 0 0 0 0-110.67346.12721.22021.4730.7797-1.90220.5033-2.5401-12.7365-32.4047-69.1492-110.6734QC'd by Selleck
Inhibitor11.5693133.590643Partial curve; high efficacy-4.93671.34430.998-128.59065-2.10 0 0 0 0 0 0 0 0 0 0-112.79886.13264.04794.49813.35553.74434.6172.9152-3.0749-34.911-75.3804-112.7988QC'd by BOC Sciences
Inhibitor8.9552108.061143Partial curve; high efficacy-5.04792.72020.9893-109.0611-1-2.10 0 0 0 0 0 0 0 0 0 0-113.6053-2.5498-0.0161-0.90541.549-1.6624-1.035-0.2871-3.0955-5.3823-47.9419-113.6053QC'd by Prestwick
Inhibitor14.5649127.955942Partial curve; high efficacy-4.83671.24750.9826-128.4559-0.5-2.10 0 0 0 0 0 0 0 0 0 0-105.98672.2922-1.30330.06040.33271.0331.7306-15.2556-2.8882-32.157-68.6091-105.9867QC'd by Microsource
Inhibitor14.949298.195442Partial curve; high efficacy-4.82541.210.9903-97.69540.5-2.10 0 0 0 0 0 0 0 0 0 0-86.60942.67262.2733-2.4477-0.1168-0.6014-1.3047-4.1854-5.4249-37.0086-59.94-86.6094QC'd by Analyticon
Inhibitor16.3421115.928742Partial curve; high efficacy-4.78671.41630.997-118.4287-2.5-2.10 0 0 0 0 0 0 0 0 0 0-99.18650.721-0.0234-3.3938-3.533-1.967-3.116-5.2659-9.9377-23.4562-59.675-99.1865QC'd by SIGMA
Inhibitor23.083990.567541Partial curve; high efficacy-4.63674.0950.9634-90.56750-2.10 0 0 0 0 0 0 0 0 0 0-83.39554.74497.57771.47721.30211.6670.6907-1.2401-5.9881-10.181-16.7566-83.3955QC'd by Specs
Inhibitor23.083975.77441Partial curve; partial efficacy-4.63674.0950.992-75.2740.5-2.20 0 0 0 0 0 0 0 0 0 0-69.52570.34681.32922.0132.5351.636-1.8741-0.19931.5465-2.9321-17.123-69.5257QC'd by MedChem Express
Inhibitor16.342192.057741Partial curve; high efficacy-4.78671.69240.9944-95.1547-3.097-2.10 0 0 0 0 0 0 0 0 0 0-84.8081-1.7048-2.7043-2.7328-3.1309-0.9142-2.2389-6.802-4.7221-18.0355-46.4212-84.8081QC'd by NCGCChem
Inhibitor25.900568.518740Partial curve; partial efficacy-4.58674.0950.9879-72.9929-4.4742-2.20 0 0 0 0 0 0 0 0 0 0-67.4188-3.157-0.3952-2.6752-3.6727-6.2029-4.4808-5.843-6.458-7.6543-12.7605-67.4188QC'd by Sequoia
Inhibitor18.336242.376921Partial curve; partial efficacy-4.73671.41630.9611-43.3769-1-2.20 0 0 0 0 0 0 0 0 0 0-38.05-3.369-1.8439-1.25460.0268-0.6973-0.09930.30380.0057-12.0993-17.8476-38.05QC'd by Microsource
Inhibitor20.573554.32321Partial curve; partial efficacy-4.68672.25260.9506-54.823-0.5-2.20 0 0 0 0 0 0 0 0 0 0-53.7485.10192.19790.06740.0829-1.10770.4012-3.1391-4.7207-8.4582-17.4267-53.748QC'd by Sytravon
Inhibitor18.336246.34721Partial curve; partial efficacy-4.73671.62590.9854-44.3472-2.20 0 0 0 0 0 0 0 0 0 0-38.90092.97871.94912.18482.73582.0412.25672.6921-0.4112-6.8174-16.7494-38.9009QC'd by Analyticon
Inhibitor14.564950.099621Partial curve; partial efficacy-4.83671.210.992-51.0996-1-2.20 0 0 0 0 0 0 0 0 0 0-41.74210.7762-0.4111-2.9919-2.3469-1.15660.2368-2.4226-3.9572-14.3837-27.3644-41.7421QC'd by Analyticon
Inhibitor20.573541.122920Partial curve; partial efficacy-4.68672.33320.9549-41.12290-2.20 0 0 0 0 0 0 0 0 0 0-40.31660.94294.30531.2929-3.02070.36030.3042-0.5695-2.7371-4.0541-12.0009-40.3166QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1217978
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2008
Volume: 4
Issue: 2
First Page: 132
Last Page: 142
DOI: 10.1038/nchembio.2007.59
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
20IC50<20000nM
20IC50<20000nM
20IC50<20000nM